WO2000048992A1 - Acylated aminoacetonitriles as cysteine protease inhibitors - Google Patents

Acylated aminoacetonitriles as cysteine protease inhibitors Download PDF

Info

Publication number
WO2000048992A1
WO2000048992A1 PCT/GB2000/000539 GB0000539W WO0048992A1 WO 2000048992 A1 WO2000048992 A1 WO 2000048992A1 GB 0000539 W GB0000539 W GB 0000539W WO 0048992 A1 WO0048992 A1 WO 0048992A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
carbamoyl
optionally substituted
sulphamoyl
alkylsulphanyl
Prior art date
Application number
PCT/GB2000/000539
Other languages
French (fr)
Inventor
Howard Tucker
Michael Stewart Large
John Oldfield
Craig Johnstone
Philip Neil Edwards
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to AU25607/00A priority Critical patent/AU2560700A/en
Priority to EP00903853A priority patent/EP1157003A1/en
Priority to JP2000599733A priority patent/JP2002537285A/en
Publication of WO2000048992A1 publication Critical patent/WO2000048992A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • C07C255/29—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton containing cyano groups and acylated amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Definitions

  • the present invention relates to compounds that are cysteine protease inhibitors and in particular compounds that are Cathepsin L inhibitors and or Cathepsin S inhibitors especially Cathepsin S inhibitors.
  • the invention further relates to processes for their preparation, to intermediates useful in their preparation, to their use as therapeutic agents, to pharmaceutical compositions containing them and to a method of treating a Cathepsin L or Cathepsin S mediated disease state.
  • Cysteine proteases are enzymes important in normal cell physiology, but they are also associated with several disease states including inflammation, metastasis, tissue damage following myocardial infarction, bone resorption and muscle wasting in dystrophic diseases.
  • Cathepsins B, H, K, L, N and S are cysteinyl proteases involved in normal protein degradation and are normally located in the lysosomes of cells. However, when these enzymes are found outside the lysosomes they have been implicated as playing a causative role in a number of disease states including bone resorption disease such as osteoporosis.
  • Living bone is continuously being remodelled and replenished by the process of resorption and deposition of the protein matrix and calcium minerals. These events are facilitated by the osteoclast, which has the ability to degrade and demineralise the bone, and the osteoblast which is responsible for new bone generation. In normal situations these processes are intimately linked resulting in little alteration of bone mass.
  • pathological conditions exist in which there is an imbalance between their activities resulting in increased degradation and demineralisation of bone and the development of fragile and/or brittle bone structure, as seen during osteoporosis.
  • Cathepsins B, H, K, L, N and S have been further implicated as playing a causative role in other diseases such as rheumatoid arthritis, osteoarthritis, tumour metastasis, pneumocystitis, Crithidia fusiculata, malaria, trypanosoma brucei brucei, schistosomiasis, periodontal disease, metachromatic leukodystrophy and muscular dystrophy.
  • Cathepsins B, H, K, L, N and S either alone or together, have also been implicated as playing a causative role in chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • US 5,055,451 discloses a series of peptidyl methyl ketones as thiol protease inhibitors;
  • WO 95/15749 discloses peptidyl ketones with heterocyclic leaving groups as cysteine protease inhibitors; the in vivo inhibition of Cathepsin B by peptidyl (acyloxy) methyl ketones was discussed in J. Med. Chem. 1994, 37, 1833-40 and these types of compounds as inhibitors of cysteine protease inhibitors were also discussed in J. Am. Chem. Soc, 1988, 110, 4429-4431 ; peptidyl diazomethyl ketones as specific inactivators of thiol proteinases was discussed in J. Biol.
  • the present invention discloses compounds with inhibitory activity of cysteine proteases and in particular of Cathepsin L and or Cathepsin S.
  • the compounds of the invention are also useful in the treatment of chronic obstructive pulmonary disease (COPD). Accordingly the present invention provides a compound of formula (I):
  • Ar is (optionally substituted phenylC 1 . 6 alkyl) 2 CH-, optionally substituted phenyl, optionally substituted naphthyl or an optionally substituted heteroaryl ring, said optional substituents being chosen from one or more of halo, C ⁇ _ 6 alkoxy, ⁇ a-kyl, nitro, C ⁇ - 6 alkanoylamino, trifluoromethyl, hydroxy, trifluoromethoxy, cyano, C ⁇ alkanoyl, - ⁇ alkanoyloxy, amino, C ⁇ .
  • R 5 is phenyl which is optionally substituted by one or more groups chosen from Ci- 6 alkyl, halo, trifluoromethyl, hydroxy, trifluoromethoxy, cyano, - ⁇ alkoxy, - ⁇ alkanoyl, C ⁇ _ 6 alkanoyloxy, amino, C ⁇ . 6 alkylamino, (C ⁇ .
  • R 1 is H or C ⁇ . 6 alkyl;
  • R 2 is H, C ⁇ .
  • R 4 is optionally substituted phenyl, or an optionally substituted 5 or 6 membered heteroaryl ring, said optional substituents on R 4 being chosen from one or more of C ⁇ _ 6 alkyl, halo, trifluoromethyl, hydroxy, trifluoromethoxy, cyano, Cj. 6 alkoxy, C ⁇ - 6 alkanoyl, amino, d- ⁇ alkylamino, (C 1 .
  • Het is a fully saturated monocyclic 5 - 8 membered heterocyclic ring, with up to 4 ring heteroatoms;
  • R 3 is H or Ci- ⁇ alkyl; or a pharmaceutically acceptable salt thereof.
  • 'alkyl' includes straight chained and branched structures and ring systems.
  • C ⁇ . 6 alkyl includes propyl, isopropyl, t-butyl, cyclopropyl and cyclohexyl.
  • references to individual alkyl groups such as 'propyl' are specific for the straight chained version only
  • references to individual branched chain alkyl groups such as 'isopropyl' are specific for the branched chain version only
  • references to individual cycloalkyl groups such as cyclohexyl are specific to the cyclic groups only.
  • aminoC ⁇ _ 6 alkyl includes 1-aminoethyl and 2-aminoethyl.
  • Het means, unless otherwise further specified, a fully saturated monocyclic 5 - 8 membered heterocyclic ring, with up to 4 ring heteroatoms. Examles of heteroatoms include nitrogen, oxygen and sulphur. Examples of “Het” include pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidyl, triazole (especially 1,2,3-triazole), piperazinyl and morpholinyl. Examples of “Het” include pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidyl, piperazinyl and morpholinyl.
  • Heteroaryl ring means, unless otherwise further specified, a monocyclic- or bicyclic- 5-12 membered ring that contains some degree of unsaturation, with up to five ring heteroatoms selected from nitrogen, oxygen and sulphur.
  • heteroaryl ring include thienyl, furyl, imidazolyl, thiazolyl, pyrimidinyl, pyridinyl, pyrrolyl, pyrazolyl, indolyl, benzimidazolyl, benzothiazolyl, quinolyl and isoquinolinyl.
  • Examples of "5- or 6- membered heteroaryl ring” include thienyl, furyl, imidazolyl, thiazolyl, pyrimidinyl, pyridinyl, pyrrolyl and pyrazolyl.
  • C ⁇ _ 6 alkanoyloxy are acetoxy and propionyloxy.
  • Examples of “Ci_ 6 alkoxycarbonyl” include methoxycarbonyl, ethoxycarbonyl, n- and t-butoxycarbonyl.
  • Examples of “C ⁇ _ 6 alkoxy” include methoxy, ethoxy and propoxy. Examples of
  • 6 alkanoylamino include formamido, acetamido and propionylamino.
  • Examples of “C]. 6 alkylsulphanyl” include methylthio and ethylthio.
  • Examples of “Q-ealkylsulphinyl” include methylsulphinyl and ethylsulphinyl.
  • Examples of " - ⁇ alkylsulphonyl” include mesyl and ethylsulphonyl.
  • Examples of “C ⁇ - 6 alkanoyl” include acetyl and propionyl.
  • Examples of “C ⁇ - 6 alkylamino” include methylamino and ethylamino.
  • N,N-(C 1 - 6 alkyl) 2 amino examples include N,N-dimethylamino, NN-diethylamino and N-ethyl-N-methylamino.
  • Examples of “C 2 . 6 alkenyl” are vinyl, allyl and 1-propenyl.
  • Examples of “C 2 . 6 alkynyl” are ethynyl, 1-propynyl and 2-propynyl.
  • Examples of "N-(C ⁇ . 6 alkyl)sulphamoyl” are N-methylsulphamoyl and N-ethylsulphamoyl. Examples of "N,N-(C 1 .
  • 6 alkyl) 2 aminoC 1 - 6 alkyl are 2-(N,N-dimethylamino)ethyl and 3-(N,N-diethylamino)propyl.
  • R 4 C). 6 alkylsulphanyl include R 4 methylthio and 2- R 4 ethylthio.
  • R 4 C 1 . 6 alkylsulphinyl include R 4 methylsulphinyl and 2- R 4 ethylsulphinyl.
  • Examples of "R 4 C 1 . alkylsulphonyl” include R 4 mesyl and 2- R 4 ethylsulphonyl. Examples of R 4 C 2 .
  • 6 alkenyl are R 4 vinyl and R 4 allyl.
  • C 2 . 6 alkynyl are R 4 ethynyl and R 4 propyn-l-yl.
  • Examples of "N-(R 4 Ci_ 6 alkyl)carbamoyl” are N-(R 4 methyl)aminocarbonyl and N-(2-R 4 ethyl)aminocarbonyl.
  • Examples of "N-(HetC ⁇ . 6 alkyl)carbamoyl” are morpholinomethylaminocarbonyl and 2- (piperidinoethyl)aminocarbonyl.
  • substituents are chosen from "one or more” groups it is to be understood that this definition includes all substituents being chosen from one of the specified groups or the substituents being chosen from two or more of the specified groups.
  • substituents are chosen from one or more halo, ⁇ alkoxy and Ci- ⁇ alkyl
  • examples of possible combinations of substituents include 1) a bromo group, 2) two chloro groups, 3) a methoxy, ethoxy and propoxy substitutent, 4) a fluoro and a methoxy group, 5) a methoxy, a methyl and an ethyl group, and 6) a chloro, a methoxy and an ethyl group.
  • the present invention provides a compound of formula (I) wherein Ar is (optionally substituted phenylC 1 . 6 alkyl) 2 CH-, optionally substituted phenyl, optionally substituted naphthyl or an optionally substituted heteroaryl ring, said optional substituents being chosen from one or more of halo, - ⁇ alkoxy, - ⁇ alkyl, nitro, C ⁇ alkanoylamino, trifluoromethyl, hydroxy, trifluoromethoxy, cyano, - ⁇ alkanoyl, C ⁇ ⁇ alkanoyloxy, amino, C ⁇ ⁇ alkylamino, N,N-(C ⁇ - 6 alkyl) 2 amino, carboxy, carbamoyl, N-(C ⁇ _ 6 alkyl)carbamoyl, N,N-(C 1 - 6 alkyl) 2 carbamoyl, C ⁇ alkoxycarbonyl, mercapto, C ⁇ _ 6 alkyls
  • R 5 is phenyl which is optionally substituted by one or more groups chosen from Ci- ⁇ alkyl, halo, trifluoromethyl, hydroxy, trifluoromethoxy, cyano, ⁇ alkoxy, d- ⁇ alkanoyl, - ⁇ alkanoyloxy, amino, C ⁇ . 6 alkylamino, N,N-(C ⁇ - alkyl) 2 amino, Cj- ⁇ alkanoylamino, nitro, carboxy, carbamoyl, N-tCi-ealky carbamoyl, N,N-(C].
  • R 1 is H or Ci-ealkyl
  • R 2 is H, C ⁇ . 6 alkyl (optionally substituted with one or more hydroxy, d. 6 alkylsulphanyl, d. 6 alkylsulphinyl, d- 6 alkylsulphonyl, R 4 , R 4 C 1 . 6 alkylsulphanyl, R 4 C ⁇ . 6 alkylsulphinyl and R 4 C 1 . 6 alkylsulphonyl), or R 2 is d_ 6 alkoxy (optionally substituted with one or more C 2 . 6 alkenyl, C 2 . 6 alkynyl, R 4 , R 4 C 2 . 6 alkenyl, R 4 C 2 .
  • R 2 is C 2 . 6 alkenyl, C 2 . 6 alkynyl, d_ 6 alkoxycarbonyl, carbamoyl, N-(d. 6 alkyl)carbamoyl, N,N-(C ⁇ . 6 alkyl) 2 carbamoyl, trifluoromethoxy, R 4 -, R 4 S-, R ⁇ - ⁇ alkylsulphanyl, N-(R 4 C 1 . 6 alkyl)carbamoyl, N-(HetC ⁇ _ 6 alkyl)carbamoyl, d.
  • R 4 is optionally substituted phenyl, or an optionally substituted 5 or 6 membered heteroaryl ring said optional substituents on R 4 being chosen from one or more of d. 6 alkyl, halo, trifluoromethyl, hydroxy, trifluoromethoxy, cyano, C ⁇ - alkoxy, d. 6 alkanoyl, d. 6 alkanoyloxy, amino, d. 6 alkylamino, N,N-(C 1 .
  • alkyl 2 amino, d_ 6 alkanoylamino, nitro, carboxy, carbamoyl, N-(d. 6 alkyl)carbamoyl, N,N-(d. 6 alkyl) 2 carbamoyl, d_ 6 alkoxycarbonyl, mercapto, d-ealkylsulphanyl, C ⁇ _ 6 alkylsulphinyl, C]. alkylsulphonyl, sulphamoyl, N-(d- 6 alkyl)sulphamoyl and N,N-(C 1 . 6 alkyl) 2 sulphamoyl; and
  • R 3 is H or C ⁇ _ 6 alkyl; or a pharmaceutically acceptable salt thereof.
  • the present invention provides a compound of formula (I) wherein Ar is phenyl substituted with 1 to 3 chloro or methyl moieties, or naphthyl substituted with 1 bromo atom; R 1 is H or d_ 6 alkyl; R 2 is H, d- 6 alkyl (optionally substituted with one or more hydroxy, Ci. 6 alkylsulphanyl, d- 6 alkylsulphinyl, d ⁇ alkylsulphonyl, R 4 , R 4 d. 6 alkylsulphanyl, R 4 d combat 6 alkylsulphinyl or R 4 d. 6 alkylsulphonyl), C].
  • alkylsulphanyl N-(R 4 d- 6 alkyl)carbamoyl, N-(HetC ⁇ . 6 alkyl)carbamoyl, d_ 6 alkanoylamino, C].
  • alkylsulphanyl Ci- ⁇ alkylsulphinyl or Cj. 6 alkylsulphonyl;
  • R 4 is optionally substituted phenyl, or an optionally substituted 5 or 6 membered heteroaryl ring, said optional substituents on R 4 being chosen from one or more of d_ 6 alkyl, halo, trifluoromethyl, hydroxy, trifluoromethoxy, cyano, C ⁇ _ 6 alkoxy, d.
  • Ar is optionally substituted phenyl or optionally substituted naphthyl said optional substituents being chosen from one or more of halo and d. 6 alkyl.
  • Ar is phenyl substituted with 1 to 3 chloro or methyl moieties, or naphthyl substituted with 1 bromo group. Particularly Ar is phenyl substituted with 2 chloro groups or naphthyl substituted with
  • Ar is 2,6-dichlorophenyl or l-bromo-napth-2-yl.
  • R 1 is hydrogen
  • R 2 is hydrogen, d_ 6 alkoxy (optionally substituted with one or more C 2 . alkynyl, R 4 , R 4 C 2 . 6 alkenyl, R 4 C 2 . 6 alkynyl or Het), d- 6 alkanoylamino, trifluoromethoxy, d_ 6 alkylsulphanyl or R 4 wherein R 4 is optionally substituted phenyl or an optionally substituted 5 or 6 membered heteroaryl ring said optional substituents being chosen from one or more d. 6 alkyl groups.
  • Het is as defined above (that is it is: a fully saturated monocyclic 5 - 8 membered heterocyclic ring, with up to 4 ring heteroatoms; for example pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidyl, piperazinyl or morpholinyl).
  • R 2 is hydrogen, d. 6 alkoxy (optionally substituted with one or more halogen, C 2 . 6 alkynyl, R 4 , R 4 C 2 . 6 alkenyl, R 4 C 2 . 6 alkynyl or Het), d_ 6 alkanoylamino, C ⁇ - 6 alkylsulphanyl or R 4 ;
  • R 4 is optionally substituted phenyl or an optionally substituted 5 or 6 membered heteroaryl ring said optional substituents being chosen from one or more Cj.
  • R 4 is optionally substituted: phenyl, pyridyl, triazolyl, pyrazolyl, furyl or thienyl.
  • Het is pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidyl, piperazinyl or morpholinyl. More preferably R 2 is hydrogen, methoxy, ethoxy, propoxy, 3-phenylprop-2-ynyloxy,
  • the present invention provides a compound of formula (I) wherein R 2 is hydrogen, methoxy, ethoxy, propoxy, 3-phenylprop-2-ynyloxy, 3-phenylprop-2-enyloxy, 2-morpholinoethoxy, acetamido, 2,2,2-trifluoroethoxy, methylthio, ethylthio, wo-propylthio, 2-propynyloxy, pyridylmethoxy, optionally substituted pyrazolyl, optionally substituted triazolyl, optionally substituted furyl, optionally substituted thienyl where said optional substituents are chosen from 1 or 2 methyl groups or said 5-membered ring is fused to a benzene ring (to form, for example, a benzotriazolyl bicyclic ring system).
  • R 2 is methoxy, ethoxy, ⁇ -propoxy, 2-morpholinoethoxy, 2-propynyloxy and isopropylthio.
  • R 3 is hydrogen.
  • Ar is optionally substituted phenyl or optionally substituted naphthyl said optional substituents being chosen from one or more of halo and d_ alkyl;
  • R 1 is hydrogen;
  • R 2 is hydrogen, d_ 6 alkoxy (optionally substituted with C 2 _ 6 alkynyl, R 4 C 2 . 6 alkenyl, R 4 C 2 . 6 alkynyl or Het), d. 6 alkanoylamino, trifluoromethoxy, Cj- 6 alkylsulphanyl or R 4 wherein R 4 is optionally substituted phenyl or an optionally substituted 5 or 6 membered heteroaryl ring said optional substituents being chosen from one or more d_ 6 alkyl groups; and R is hydrogen; or a pharmaceutically acceptable salt thereof.
  • Het is as defined above (that is it is: a fully saturated monocyclic 5 - 8 membered heterocyclic ring, with up to 4 ring heteroatoms; for example pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidyl, piperazinyl or morpholinyl).
  • a further preferred class of compounds is that of formula (I) wherein: Ar is phenyl substituted with 2 chloro groups or naphthyl substituted with 1 bromo group;
  • R 1 is hydrogen
  • R is methoxy, ethoxy, n-propoxy, 2-morpholinoethoxy, 2-propynyloxy or isopropylthio; and R 3 is hydrogen; or a pharmaceutically acceptable salt thereof.
  • the present invention provides a compound of formula (I) wherein Ar is phenyl optionally substituted with halogen (such as chlorine) or C M alkyl (such as methyl), or naphthyl optionally substituted by halogen (such as bromo); R 1 and R 3 are both hydrogen; and R 2 is hydrogen, d- 6 alkoxy (optionally substituted by halogen (such as fluorine), pyridinyl or morpholinyl), d-6 alkylthio, C 2 . 6 alkenyloxy (optionally substituted by phenyl), C 2 .
  • halogen such as chlorine
  • C M alkyl such as methyl
  • halogen such as bromo
  • R 1 and R 3 are both hydrogen
  • R 2 is hydrogen, d- 6 alkoxy (optionally substituted by halogen (such as fluorine), pyridinyl or morpholinyl), d-6 alkylthio, C 2 . 6 alkenyloxy (option
  • Preferred compounds are those of Examples 1 - 26 or a pharmaceutically acceptable salt thereof.
  • the present invention provides a compound of formula (I) wherein Ar is phenyl disubstituted with halogen (such as chlorine), or naphthyl monosubstituted by halogen (such as bromo); R and R are both hydrogen; and R is Cj. 6 alkoxy (optionally substituted by morpholinyl), d_ 6 alkylthio or C 2 . 6 alkynyloxy; or a pharmaceutically acceptable salt.
  • R 2 is, for example, methoxy, ethoxy, n-propoxy, .s ⁇ -propylthio, 2- propynyloxy or 2-morpholinoethoxy.
  • Especially preferred compounds are those of Examples 1, 3, 5, 8, 10, 16 or 19 or a pharmaceutically acceptable salt thereof.
  • Suitable pharmaceutically acceptable salts include acid addition salts such as the methanesulphonate, fumarate, hydrochloride, hydrobromide, citrate and maleate salts and salts formed with phosphoric and sulphuric acid.
  • suitable salts are base salts such as an alkali metal salt for example a sodium salt, an alkaline earth metal salt for example a calcium or a magnesium salt, an organic amine salt for example a salt with triethylamine, morpholine, N-methylpiperidine, N-ethylpiperidine, procaine, dibenzylamine, NN-dibenzylethylamine or an amino acid for example a lysine salt.
  • base salts such as an alkali metal salt for example a sodium salt, an alkaline earth metal salt for example a calcium or a magnesium salt, an organic amine salt for example a salt with triethylamine, morpholine, N-methylpiperidine, N-ethylpiper
  • a preferred pharmaceutically acceptable salt is a sodium salt.
  • Some compounds of formula (I) may possess chiral centres. It is to be understood that the invention encompasses all such optical isomers and diasteroisomers of compounds of formula (I) which possess cysteine protease inhibitory activity.
  • the invention further relates to all tautomeric forms of the compounds of formula (I). It is also to be understood that certain compounds of the formula (I) can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms.
  • Another aspect of the present invention provides a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof. According to this aspect of the invention there is provided a process (in which variable groups are as defined for formula (I) unless otherwise stated) which comprises:
  • a suitable reactive derivative of an acid of the formula (II) is, for example, an acyl halide, for example an acyl chloride formed by the reaction of the acid and an inorganic acid chloride, for example thionyl chloride; a mixed anhydride, for example an anhydride formed by the reaction of the acid and a chloroformate such as isobutyl chloroformate; an active ester, for example an ester formed by the reaction of the acid and a phenol such as pentafluorophenol, an ester such as pentafluorophenyl trifluoroacetate, an alcohol such as 1- hydroxybenzotriazole or a uronium salt such as 2-(l-benzotriazolyl)-l, 1,3,3- tetramethyluronium hexafluorophosphate(V); an acyl azide, for example an azide formed by the reaction of the acid and an azide such as diphenyl
  • the reaction is preferably carried out in the presence of a suitable base such as, for example, an alkali or alkaline earth metal carbonate, alkoxide or hydroxide, for example sodium carbonate or potassium carbonate, or, for example, an organic amine base such as, for example, pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine or diazabicyclo-[5.4.0]undec-7-ene.
  • a suitable base such as, for example, an alkali or alkaline earth metal carbonate, alkoxide or hydroxide, for example sodium carbonate or potassium carbonate, or, for example, an organic amine base such as, for example, pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine or diazabicyclo-[5.4.0]undec-7-ene.
  • the reaction is also preferably carried out in a suitable inert solvent or diluent, for example methylene chloride, acetonitrile, tetrahydrofuran, 1 ,2- dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-one or dimethylsulphoxide, and at a temperature in the range, for example, -78° to 150°C, conveniently at or near ambient temperature.
  • a suitable inert solvent or diluent for example methylene chloride, acetonitrile, tetrahydrofuran, 1 ,2- dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-one or dimethylsulphoxide, and at a temperature in the range, for example, -78° to 150°C, conveniently at or near ambient temperature.
  • a dehydration reaction may conventionally be carried out by reaction with a reagent such as trifluoroacetic anhydride.
  • the reaction can conveniently be conducted in the presence of a suitable base as defined hereinbefore such as, for example, triethylamine.
  • the reaction is also preferably carried out in a suitable inert solvent or diluent, as defined hereinbefore such as dichloromethane and at a temperature in the range, for example, -10°C to reflux conveniently 10°C to reflux.
  • the necessary starting materials for the procedures described above may be made by procedures which are selected from standard organic chemical techniques, techniques which are analogous to the synthesis of known, structurally similar compounds, by techniques which are analogous to the above described procedures or by techniques which are analogous to the procedures described in the examples.
  • aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and a Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halogeno group.
  • modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl.
  • reactants include groups such as amino, carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned herein.
  • a suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or t-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl.
  • the deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group.
  • an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • an acyl group such as a t-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate).
  • a suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.
  • a suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl.
  • the deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group.
  • an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
  • a suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a t-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
  • a base such as sodium hydroxide
  • a t-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
  • the protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.
  • a compound of the formula (I), or a pharmaceutically acceptable salt thereof for use in a method of treatment of the human or animal body by therapy.
  • a method for producing inhibition of a cysteine protease in a warm blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof.
  • the invention also provides a compound of the formula wherein Ar is (optionally substituted phenylC 1 .
  • R 5 is phenyl which is optionally substituted by one or more groups chosen from d_ 6 alkyl, halo, trifluoromethyl, hydroxy, trifluoromethoxy, cyano, d- 6 alkoxy, C ⁇ 6 alkanoyl, d. 6 alkanoyloxy, amino, C ⁇ _ 6 alkylamino, (C 1 . 6 alkyl) 2 amino, nitro, carboxy, carbamoyl, N-(d_ 6 alkyl)carbamoyl, N,N-(d_ 6 alkyl) carbamoyl, C 1 .
  • R 4 is optionally substituted phenyl, or an optionally substituted 5 or 6 membered heteroaryl ring, said optional substituents on R 4 being chosen from one or more of d. 6 alkyl, halo, trifluoromethyl, hydroxy, trifluoromethoxy, cyano, d- 6 alkoxy, d- ⁇ alkanoyl, d. 6 alkanoyloxy, amino, d. 6 alkylamino, (C 1 .
  • R 3 is H or C ⁇ _ 6 alkyl; or a pharmaceutically acceptable salt thereof; for use as a medicament.
  • the present invention provides the use of a compound of the formula (I), wherein Ar is (optionally substituted phenylC 1 _ 6 alkyl) 2 CH-, optionally substituted phenyl, optionally substituted naphthyl or an optionally substituted heteroaryl ring, said optional substituents being chosen from one or more of halo, Cj. 6 alkyl, nitro, C ⁇ _ alkanoylamino, trifluoromethyl, hydroxy, trifluoromethoxy, cyano, C ⁇ _ 6 alkanoyl, d_ 6 alkanoyloxy, amino, d_ 6 alkylamino, (C 1 .
  • R 5 is phenyl which is optionally substituted by one or more groups chosen from C ⁇ . 6 alkyl, halo, trifluoromethyl, hydroxy, trifluoromethoxy, cyano, C ⁇ _ 6 alkoxy, C ⁇ - 6 alkanoyl, d_ 6 alkanoyloxy, amino, d_ 6 alkylamino, (C 1 . 6 alkyl) 2 amino, d.
  • R 1 is H or d ⁇ alkyl
  • R 2 is H, d_ 6 alkyl (optionally substituted with one or more hydroxy, d- ⁇ alkylsulphanyl, C ⁇ . 6 alkylsulphonyl, R 4 , R 4 C 1 . 6 alkylsulphanyl, R 4 d. 6 alkylsulphinyl or R 4 d_ alkylsulphonyl), d_ 6 alkoxy (optionally substituted with one or more halogen,
  • R 4 is optionally substituted phenyl, or an optionally substituted 5 or 6 membered heteroaryl ring, said optional substituents on R 4 being chosen from one or more of d- alkyl, halo, trifluoromethyl, hydroxy, trifluoromethoxy, cyano, d ⁇ alkoxy, d. 6 alkanoyl, d.
  • the invention further provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of chronic obstructive pulmonary disease (COPD) in a warm blooded animal, such as man.
  • COPD chronic obstructive pulmonary disease
  • the invention provides the use of a compound of the formula (I) of the present invention, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the inhibition of Cathepsin S in a warm blooded animal, such as man.
  • the invention also provides the use of a compound of the formula (I) of the present invention, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the inhibition of Cathepsin L in a warm blooded animal, such as man.
  • the present invention further provides a method of treating a Cathepsin L or Cathepsin S mediated disease state in mammals which comprises administering to a mammal in need of such treatment an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.
  • a compound of the formula (I) or a pharmaceutically acceptable salt thereof for the therapeutic treatment of mammals including humans, in particular in the inhibition of a cysteine protease, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition. Therefore in another aspect the present invention provides a pharmaceutical composition which comprises a compound of the formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent or carrier.
  • compositions of this invention may be administered in standard manner for the disease condition that it is desired to treat, for example by oral, rectal or parenteral administration.
  • the compounds of this invention may be formulated by means known in the art into the form of, for example, tablets, capsules, aqueous or oily solutions or suspensions, (lipid) emulsions, dispersible powders, suppositories, ointments, creams, drops and sterile injectable aqueous or oily solutions or suspensions.
  • a suitable pharmaceutical composition of this invention is one suitable for oral administration in unit dosage form, for example a tablet or capsule which contains between 100 mg and 1 g of the compound of this invention.
  • a pharmaceutical composition of the invention is one suitable for intravenous, subcutaneous or intramuscular injection.
  • Each patient may receive, for example, an intravenous, subcutaneous or intramuscular dose of 1 mgkg 1 to 100 mgkg "1 of the compound, preferably in the range of 5 mgkg "1 to 20 mgkg "1 of this invention, the composition being administered 1 to 4 times per day.
  • the intravenous, subcutaneous and intramuscular dose may be given by means of a bolus injection.
  • the intravenous dose may be given by continuous infusion over a period of time.
  • each patient will receive a daily oral dose which is approximately equivalent to the daily parenteral dose, the composition being administered 1 to 4 times per day.
  • Buffers such as polyethylene glycol, polypropylene glycol, glycerol or ethanol or complexing agents such as hydroxy-propyl ⁇ cyclodextrin may be used to aid formulation.
  • the above formulations may be obtained by conventional procedures well known in the pharmaceutical art.
  • the tablets (a)-(c) may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate.
  • the pharmaceutically-acceptable compounds of the present invention are useful in the inhibition of Cathepsin L and Cathepsin S, having a good activity in vitro against human Cathepsin L, human Cathepsin S and rabbit Cathepsin L.
  • Rabbit Cathepsin L was purified from rabbit liver as described by Maciewicz R. A. and Etherington D. J. (Biochem. J. (1988) 256, 433-440) except the liver homogenate supernatant was concentrated by fractionation with (NHU) 2 SO (20-80% saturation), and the pellet taken up and dialysed against 20mM NaAcetate pH 5.5, ImM ethylenediaminetetraacetic acid (EDTA). The supernatant was then applied to a CM Sepharose ion exchange column and Cathepsin L eluted by gradient elution (0.25-0.75M NaCl). Fraction activity was determined using the 5 synthetic substrate NCBz-Phe-Arg-NHMec as described.
  • Cathepsin L fractions were pooled and desalted on a Sephacryl SI 00 column. Active fractions were pooled, adjusted to 20% saturation (NH 4 ) 2 SO 4 and concentrated on a phenyl sepharose column. The remaining purification steps were as described.
  • Cathepsin L activity was measured based on the method of Barrett and Kirschke (1981).
  • the PCR was done so as to introduce an EcoRI cloning site 5' of the 'ATG' of Cathepsin S and an Xbal cloning site 3' of the 'Stop' codon.
  • the PCR product was cloned between the EcoRI and Xbal sites of the baculovirus transfer vector pFASTBAC-1 (Bac-to- Bac Expression System commercially available from Gibco BRL -Life Technologies ( cat no 5 10359-016)). This recombinant construct was used to generate, by standard techniques, a recombinant baculovirus capable of expressing preprocathepsin S.
  • Cathepsin S was tested for the baculoviral constructs by infection of two insect cell lines : Sf9 cells (ATCC No CRL-1711) and T.ni cells (Invitrogen, Cat No B855-02). 10 Purification of Cathepsin S Method 1.
  • Procathepsin S was found in the insect cell medium and acid activated.
  • the medium was mixed with an equal volume of lOOmM Sodium Acetate buffer pH 4.5, 5mM dithiothreitol (DTT) and 5mM EDTA and incubated for one hour at 37°C method of Maubach 15 et al (Eur. J. Biochem., 250, 745-750, 1997).
  • the pH of insect cell medium (10ml) containing procathepsin S was adjusted to 4.5 with glacial acetic acid and DTT and EDTA added to 5mM. The sample was then incubated at
  • Cathepsin S activity was measured based on the method of Maubach et al (Eur. J. Biochem., 250, 745-750, 1997), using the fluorogenic substrate Z-Nal-Val-Arg-NHMec. Inhibitors were identified by their ability to decrease the generation of the fluorescent leaving group (NHMec). Briefly the assay was as follows: rHuman Cathepsin S (1.5 nmoles) was pre-incubated with or without compounds in 50mM Potassium phosphate buffer pH 6.0-6.2, 20mM Na 2 EDTA, 0.1% Brij at 25°C for 5 minutes in a solid black 96 well plate.
  • Synthetic substrate 20 ⁇ M Z-Val-Val-Arg-NHMec
  • 20 ⁇ M Z-Val-Val-Arg-NHMec was added and the mixture incubated at 30°C for 20 minutes.
  • the reaction was stopped by the addition of 0.1M sodium chloroacetate pH 4.3.
  • Fluorescence was determined using a Fluoroskan II plate reader; excitation 355nm, emission 460nm.
  • Compound potency was determined from the raw fluorescence data by calculating the IC 50 against Cathepsin S using a PC graph drawing software package.
  • temperatures are given in degrees Celsius (°C); operations were carried out at room or ambient temperature, that is, at a temperature in the range of 18-25°C;
  • organic solutions were dried over anhydrous magnesium sulphate; evaporation of solvent was carried out using a rotary evaporator under reduced pressure (600-4000 Pascals; 4.5-30 mm Hg) with a bath temperature of up to 60°C;
  • chromatography means flash chromatography on silica gel; thin layer chromatography (TLC) was carried out on silica gel plates;
  • NMR data is in the form of delta values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard, determined at 250 MHz using perdeuterio dimethyl sulphoxide (DMSO- ⁇ 6 ) as the solvent unless otherwise stated;
  • melting points are uncorrected and (dec) indicates decomposition; the melting points given are those obtained for the materials prepared as described; polymorphism may result in isolation of materials with different melting points in some preparations.
  • Trifluoroacetic anhydride (0.51 ml) was added dropwise to a stirred mixture of 2-(2,6- dichlorobenzamido)-2-propoxyacetamide (360 mg) in pyridine (5 ml) at -10°C. The mixture was allowed to warm to ambient temperature then poured into ice-water and extracted with ether. The organic phase was washed with brine, dried and evaporated to dryness under reduced pressure. The residue was triturated with hexane and the insoluble solid collected to give 2-(2,6-dichlorobenzamido)-2-propoxyacetonitrile (235 mg).
  • Example 17 2-(l-bromo-2- naphthoylamino)-2-isopropylthioacetamide as starting material to give 2-(l-bromo-2- naphthoylamino)-2-isopropylthioacetonitrile.
  • Example 17 2-(2.4-Dichlorobenzamido)-2-isopropylthioacetonitrile
  • Example 18 The process described in Example 2 was repeated using 2-(2,4-dichlorobenzamido)-2- isopropylthioacetamide as starting material to give 2-(2,4-dichlorobenzamido)-2- isopropylthioacetonitrile.
  • Example 18 Example 18
  • Example 20 2-(2,4-Dichlorobenzamido)-2-methoxyacetonitrile The process described in Example 19 was repeated using 2-(2,4-dichlorobenzamido)-2- isopropylthioacetonitrile as starting material to give 2-(2,4-dichlorobenzamido)-2- methoxyacetonitrile.
  • Example 21 2-( 1 -Bromo-2-naphthoylamino)acetonitrile
  • N,N-Dimethylformamide (0.05 ml) was added to a stirred mixture of l-bromo-2- naphthoic acid (2 g) , dichloromethane (20 ml) and oxalyl chloride ( (0.9 ml) and the mixture was stirred for 1 hour then evaporated to dryness under reduced pressure.

Abstract

A compound of formula (I): wherein R?1, R2, R3¿ and Ar are defined; a composition comprising a compound of formula (I) and a carrier or diluent; a compound of formula (I) for use as a medicament; the use of a compound of formula (I) in the manufacture of a medicament for use in the inhibition of a cysteine protease in a warm blooded animal; the use of a compound of formula (I) in the manufacture of a medicament for use in the treatment of chronic obstructive pulmonary disease in a warm blooded animal; and a method of treating a Cathepsin L or Cathepsin S mediated disease state in mammals which comprises administering to a mammal in need of such treatment an effective amount of a compound of formula (I).

Description

ACYLATED AMINOACETONITRILES AS CYSTEINE PROTEASE INHIBITORS
The present invention relates to compounds that are cysteine protease inhibitors and in particular compounds that are Cathepsin L inhibitors and or Cathepsin S inhibitors especially Cathepsin S inhibitors. The invention further relates to processes for their preparation, to intermediates useful in their preparation, to their use as therapeutic agents, to pharmaceutical compositions containing them and to a method of treating a Cathepsin L or Cathepsin S mediated disease state.
Cysteine proteases are enzymes important in normal cell physiology, but they are also associated with several disease states including inflammation, metastasis, tissue damage following myocardial infarction, bone resorption and muscle wasting in dystrophic diseases.
Cathepsins B, H, K, L, N and S are cysteinyl proteases involved in normal protein degradation and are normally located in the lysosomes of cells. However, when these enzymes are found outside the lysosomes they have been implicated as playing a causative role in a number of disease states including bone resorption disease such as osteoporosis.
The number of people living to an old age has increased dramatically in recent years. This has been marked by an increase in the number of people having osteoporosis and other diseases associated with old age. Osteoporosis is accompanied by a high incidence of bone fracture resulting in many aged patients being confined to their beds. There is therefore a great need for a pharmaceutical composition to treat or prevent this disease.
Living bone is continuously being remodelled and replenished by the process of resorption and deposition of the protein matrix and calcium minerals. These events are facilitated by the osteoclast, which has the ability to degrade and demineralise the bone, and the osteoblast which is responsible for new bone generation. In normal situations these processes are intimately linked resulting in little alteration of bone mass. However, pathological conditions exist in which there is an imbalance between their activities resulting in increased degradation and demineralisation of bone and the development of fragile and/or brittle bone structure, as seen during osteoporosis. While the exact mechanism for this resorption is not known, increased osteoclast activity, as realised by increased proteolytic activity, is a contributing factor, and selective inhibition of proteolytic action may result in the arrest or reversal of bone loss. The lysosomal cysteine proteinases, Cathepsins B, H, K, L, N and S have been postulated as the proteinases that are responsible for osteoclast bone resorption, because of their ability to degrade insoluble type I collagens at low pH.
Cathepsins B, H, K, L, N and S have been further implicated as playing a causative role in other diseases such as rheumatoid arthritis, osteoarthritis, tumour metastasis, pneumocystitis, Crithidia fusiculata, malaria, trypanosoma brucei brucei, schistosomiasis, periodontal disease, metachromatic leukodystrophy and muscular dystrophy. Cathepsins B, H, K, L, N and S, either alone or together, have also been implicated as playing a causative role in chronic obstructive pulmonary disease (COPD). In recent years a number of synthetic inhibitors of cysteine proteases have been disclosed. US 5,055,451 discloses a series of peptidyl methyl ketones as thiol protease inhibitors; WO 95/15749 discloses peptidyl ketones with heterocyclic leaving groups as cysteine protease inhibitors; the in vivo inhibition of Cathepsin B by peptidyl (acyloxy) methyl ketones was discussed in J. Med. Chem. 1994, 37, 1833-40 and these types of compounds as inhibitors of cysteine protease inhibitors were also discussed in J. Am. Chem. Soc, 1988, 110, 4429-4431 ; peptidyl diazomethyl ketones as specific inactivators of thiol proteinases was discussed in J. Biol. Chem., 1981, 256, 4, 1923-8 and in Methods in Enzymology, 1981, 80, 820-5; the inhibiting activities of l-peptidyl-2-haloacetyl hydrazines towards Cathepsin B and calpains was discussed in Ewr. J. Med. Chem., 1993, 28 297-311 and peptidyl fluoromethyl ketones as inhibitors of Cathepsin B and the implication for treatment of Rheumatoid arthritis was discussed in Biochemical Pharmacology, 1992, 44, 6, 1201-7. Thus, there is a great need for a specific cysteine protease inhibitor, especially a Cathepsin L inhibitor or a Cathepsin S inhibitor.
The present invention discloses compounds with inhibitory activity of cysteine proteases and in particular of Cathepsin L and or Cathepsin S. The compounds of the invention are also useful in the treatment of chronic obstructive pulmonary disease (COPD). Accordingly the present invention provides a compound of formula (I):
Figure imgf000005_0001
(I) wherein
Ar is (optionally substituted phenylC1.6alkyl)2CH-, optionally substituted phenyl, optionally substituted naphthyl or an optionally substituted heteroaryl ring, said optional substituents being chosen from one or more of halo, Cι_6alkoxy, ^a-kyl, nitro, Cι-6alkanoylamino, trifluoromethyl, hydroxy, trifluoromethoxy, cyano, Cμβalkanoyl, -βalkanoyloxy, amino, Cι.6alkylamino, ( -δalkyl^amino, carboxy, carbamoyl, N-(Cι_6alkyl)carbamoyl, N,N-(Cι_6alkyl)2carbamoyl, Cj-όalkoxycarbonyl, mercapto, Cι_6alkylsulphanyl, Cι.6alkylsulphinyl, Cι.6alkylsulphonyl, sulphamoyl, N-(Cι.6alkyl)sulphamoyl,
Figure imgf000005_0002
N-CCi-ealky aminoCLealkyl, ( .ealkyl^amino .ealkyl, R5S-, R5C(O)- or R5CH2-; R5 is phenyl which is optionally substituted by one or more groups chosen from Ci-6alkyl, halo, trifluoromethyl, hydroxy, trifluoromethoxy, cyano, -όalkoxy, -βalkanoyl, Cι_6alkanoyloxy, amino, Cι.6alkylamino, (Cι.6alkyl)2amino, Cι-6alkanoylamino, nitro, carboxy, carbamoyl,
Figure imgf000005_0003
N,N-(Cι„ alkyl)2carbamoyl, d.6alkoxycarbonyl, mercapto, C^όalkylsulphanyl, C].6alkylsulphinyl, -όalkylsulphonyl, sulphamoyl, -V-(Cι.6alkyl)sulphamoyl or N,N-(C1-6alkyl) sulphamoyl; R1 is H or Cι.6alkyl; R2 is H, Cι.6alkyl (optionally substituted with one or more hydroxy, ^alkylsulphanyl, -όalkylsulphinyl,
Figure imgf000005_0004
R4Ci.6alkylsulphinyl or R4Cι.6alkylsulphonyl), C^alkoxy (optionally substituted with one or more halogen, C2.6alkenyl, C2.6alkynyl, R4, R4C2.6alkenyl, R4C2. alkynyl or Het), C2.6alkenyl, C2.6alkynyl, C\.(, alkoxycarbonyl, carbamoyl, N-C ^alky^carbamoyl, N,N-(Cι-6alkyl) carbamoyl, R4-, R4S-, R4Cι.6alkylsulphanyl, N-(R4Ci.6alkyl)carbamoyl, N-(HetC1.6alkyl)carbamoyl, Ci-ealkanoylamino, d^alkylsulphanyl, Cμδalkylsulphinyl or d-όalkylsulphonyl; R4 is optionally substituted phenyl, or an optionally substituted 5 or 6 membered heteroaryl ring, said optional substituents on R4 being chosen from one or more of Cι_6alkyl, halo, trifluoromethyl, hydroxy, trifluoromethoxy, cyano, Cj.6alkoxy, Cι-6alkanoyl,
Figure imgf000006_0001
amino, d-βalkylamino, (C1.6alkyl)2amino, -ealkanoylamino, nitro, carboxy, carbamoyl, N-(Cι.6alkyl)carbamoyl, N,N-(C!.6alkyl)2carbamoyl, Cj.6alkoxycarbonyl, mercapto, Cμδalkylsulphanyl, d-όalkylsulphinyl, Q-βalkylsulphonyl, sulphamoyl, N- Q-όalky sulphamoyl or N,N-(C1.6alkyl)2sulphamoyl, wherein two such adjacent groups may join to form a 6-membered saturated, partially saturated or unsaturated ring;
Het is a fully saturated monocyclic 5 - 8 membered heterocyclic ring, with up to 4 ring heteroatoms; and
R3 is H or Ci-βalkyl; or a pharmaceutically acceptable salt thereof.
In this specification the term 'alkyl' includes straight chained and branched structures and ring systems. For example, Cι.6alkyl includes propyl, isopropyl, t-butyl, cyclopropyl and cyclohexyl. However, references to individual alkyl groups such as 'propyl' are specific for the straight chained version only, references to individual branched chain alkyl groups such as 'isopropyl' are specific for the branched chain version only and references to individual cycloalkyl groups such as cyclohexyl are specific to the cyclic groups only.
A similar convention applies to other radicals, for example "aminoCι_6alkyl" includes 1-aminoethyl and 2-aminoethyl.
The term "halo" refers to fluoro, chloro, bromo and iodo. "Het" means, unless otherwise further specified, a fully saturated monocyclic 5 - 8 membered heterocyclic ring, with up to 4 ring heteroatoms. Examles of heteroatoms include nitrogen, oxygen and sulphur. Examples of "Het" include pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidyl, triazole (especially 1,2,3-triazole), piperazinyl and morpholinyl. Examples of "Het" include pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidyl, piperazinyl and morpholinyl.
"Heteroaryl ring " means, unless otherwise further specified, a monocyclic- or bicyclic- 5-12 membered ring that contains some degree of unsaturation, with up to five ring heteroatoms selected from nitrogen, oxygen and sulphur. Examples of "heteroaryl ring" include thienyl, furyl, imidazolyl, thiazolyl, pyrimidinyl, pyridinyl, pyrrolyl, pyrazolyl, indolyl, benzimidazolyl, benzothiazolyl, quinolyl and isoquinolinyl. Examples of "5- or 6- membered heteroaryl ring" include thienyl, furyl, imidazolyl, thiazolyl, pyrimidinyl, pyridinyl, pyrrolyl and pyrazolyl.
Examples of "Cι_6alkanoyloxy" are acetoxy and propionyloxy. Examples of "Ci_6alkoxycarbonyl" include methoxycarbonyl, ethoxycarbonyl, n- and t-butoxycarbonyl. Examples of "Cι_6alkoxy" include methoxy, ethoxy and propoxy. Examples of
"C].6alkanoylamino" include formamido, acetamido and propionylamino. Examples of "C].6alkylsulphanyl" include methylthio and ethylthio. Examples of "Q-ealkylsulphinyl" include methylsulphinyl and ethylsulphinyl. Examples of " -όalkylsulphonyl" include mesyl and ethylsulphonyl. Examples of "Cι-6alkanoyl" include acetyl and propionyl. Examples of "Cι-6alkylamino" include methylamino and ethylamino. Examples of "N,N-(C1-6alkyl)2amino" include N,N-dimethylamino, NN-diethylamino and N-ethyl-N-methylamino. Examples of "C2.6alkenyl" are vinyl, allyl and 1-propenyl. Examples of "C2.6alkynyl" are ethynyl, 1-propynyl and 2-propynyl. Examples of "N-(Cι.6alkyl)sulphamoyl" are N-methylsulphamoyl and N-ethylsulphamoyl. Examples of "N,N-(C1.6alkyl)2sulphamoyl" are NN-dimethylsulphamoyl and N,N-diethylsulphamoyl. Examples of "N-(Cι_6alkyl)carbamoyl" are methylaminocarbonyl and ethylaminocarbonyl. Examples of "N,N-(Cι-6alkyl)2carbamoyl" are N,N-dimethylaminocarbonyl and N,N-diethylaminocarbonyl. Examples of
Figure imgf000007_0001
are 2-N-methylaminoethyl and 3-N-ethylaminopropyl. Examples of "N,N-(C1.6alkyl)2aminoC1-6alkyl" are 2-(N,N-dimethylamino)ethyl and 3-(N,N-diethylamino)propyl. Examples of "R4C).6alkylsulphanyl" include R4methylthio and 2- R4ethylthio. Examples of "R4C1.6alkylsulphinyl" include R4methylsulphinyl and 2- R4ethylsulphinyl. Examples of "R4C1. alkylsulphonyl" include R4mesyl and 2- R4ethylsulphonyl. Examples of R4C2.6alkenyl are R4vinyl and R4allyl. Examples of "C2.6alkynyl" are R4ethynyl and R4propyn-l-yl. Examples of "N-(R4Ci_6alkyl)carbamoyl" are N-(R4methyl)aminocarbonyl and N-(2-R4ethyl)aminocarbonyl. Examples of "N-(HetCι.6alkyl)carbamoyl" are morpholinomethylaminocarbonyl and 2- (piperidinoethyl)aminocarbonyl.
Where optional substituents are chosen from "one or more" groups it is to be understood that this definition includes all substituents being chosen from one of the specified groups or the substituents being chosen from two or more of the specified groups. For example where optional substituents are chosen from one or more halo, ^alkoxy and Ci-βalkyl, examples of possible combinations of substituents include 1) a bromo group, 2) two chloro groups, 3) a methoxy, ethoxy and propoxy substitutent, 4) a fluoro and a methoxy group, 5) a methoxy, a methyl and an ethyl group, and 6) a chloro, a methoxy and an ethyl group. In one particular aspect the present invention provides a compound of formula (I) wherein Ar is (optionally substituted phenylC1.6alkyl)2CH-, optionally substituted phenyl, optionally substituted naphthyl or an optionally substituted heteroaryl ring, said optional substituents being chosen from one or more of halo, -βalkoxy, -όalkyl, nitro, C^alkanoylamino, trifluoromethyl, hydroxy, trifluoromethoxy, cyano, -όalkanoyl, Cμόalkanoyloxy, amino, C^όalkylamino, N,N-(Cι-6alkyl)2amino, carboxy, carbamoyl, N-(Cι_6alkyl)carbamoyl, N,N-(C1-6alkyl)2carbamoyl, C^alkoxycarbonyl, mercapto, Cι_6alkylsulphanyl, Cι-6alkylsulphinyl, Cι.6alkylsulphonyl, sulphamoyl, N-(Cι_6alkyl)sulphamoyl, N,N-(C1.6alkyl)2sulphamoyl, aminoCι.6alkyl, Λ '-CCi-βalky aminoCi-βalkyI, N,N-(C1.6alkyl)2aminoC1.6alkyl, R5S-, R5C(O)- and R5CH2- wherein R5 is phenyl which is optionally substituted by one or more groups chosen from Ci-βalkyl, halo, trifluoromethyl, hydroxy, trifluoromethoxy, cyano, ^alkoxy, d-όalkanoyl, -όalkanoyloxy, amino, Cι.6alkylamino, N,N-(Cι- alkyl)2amino, Cj-βalkanoylamino, nitro, carboxy, carbamoyl, N-tCi-ealky carbamoyl, N,N-(C].6alkyl)2carbamoyl, d-βalkoxycarbonyl, mercapto, Cι_6alkylsulphanyl, Cμόalkylsulphinyl, d-βalkylsulphonyl, sulphamoyl, N-(C1.6alkyl)sulphamoyl and N,N-(C1.6alkyl)2sulphamoyl; R1 is H or Ci-ealkyl;
R2 is H, Cι.6alkyl (optionally substituted with one or more hydroxy, d.6alkylsulphanyl, d.6alkylsulphinyl, d-6alkylsulphonyl, R4, R4C1.6alkylsulphanyl, R4Cι.6alkylsulphinyl and R4C1.6alkylsulphonyl), or R2 is d_6alkoxy (optionally substituted with one or more C2.6alkenyl, C2.6alkynyl, R4, R4C2.6alkenyl, R4C2.6alkynyl and Het), or R2 is C2.6alkenyl, C2.6alkynyl, d_6alkoxycarbonyl, carbamoyl, N-(d.6alkyl)carbamoyl, N,N-(Cι.6alkyl)2carbamoyl, trifluoromethoxy, R4-, R4S-, R^-όalkylsulphanyl, N-(R4C1.6alkyl)carbamoyl, N-(HetCι_6alkyl)carbamoyl, d.6alkanoylamino, d_6alkylsulphanyl, d-6alkylsulphinyl or d-βalkylsulphonyl wherein R4 is optionally substituted phenyl, or an optionally substituted 5 or 6 membered heteroaryl ring said optional substituents on R4 being chosen from one or more of d.6alkyl, halo, trifluoromethyl, hydroxy, trifluoromethoxy, cyano, Cι- alkoxy, d.6alkanoyl, d.6alkanoyloxy, amino, d.6alkylamino, N,N-(C1.6alkyl)2amino, d_6alkanoylamino, nitro, carboxy, carbamoyl, N-(d.6alkyl)carbamoyl, N,N-(d.6alkyl)2carbamoyl, d_6alkoxycarbonyl, mercapto, d-ealkylsulphanyl, Cι_6alkylsulphinyl, C]. alkylsulphonyl, sulphamoyl, N-(d-6alkyl)sulphamoyl and N,N-(C1.6alkyl)2sulphamoyl; and
R3 is H or Cι_6alkyl; or a pharmaceutically acceptable salt thereof.
In a still further aspect the present invention provides a compound of formula (I) wherein Ar is phenyl substituted with 1 to 3 chloro or methyl moieties, or naphthyl substituted with 1 bromo atom; R1 is H or d_6alkyl; R2 is H, d-6alkyl (optionally substituted with one or more hydroxy, Ci.6alkylsulphanyl, d-6alkylsulphinyl, d^alkylsulphonyl, R4, R4d.6alkylsulphanyl, R4d„6alkylsulphinyl or R4d.6alkylsulphonyl), C].6alkoxy (optionally substituted with one or more halogen, C2.6alkenyl, C2.6alkynyl, R4, R4C2-6alkenyl, R4C2.6alkynyl or Het), C2. alkenyl, C2.6alkynyl, Cι.6 alkoxycarbonyl, carbamoyl, N-(Cι.6alkyl)carbamoyl, N,N-(d_6alkyl)2carbamoyl, R4-, R4S-, R4Cι.6alkylsulphanyl, N-(R4d-6alkyl)carbamoyl, N-(HetCι.6alkyl)carbamoyl, d_6alkanoylamino, C]. alkylsulphanyl, Ci-όalkylsulphinyl or Cj.6alkylsulphonyl; R4 is optionally substituted phenyl, or an optionally substituted 5 or 6 membered heteroaryl ring, said optional substituents on R4 being chosen from one or more of d_6alkyl, halo, trifluoromethyl, hydroxy, trifluoromethoxy, cyano, Cι_6alkoxy, d.6alkanoyl, d-6alkanoyloxy, amino, C].6alkylamino, (Cι.6alkyl) amino, Cι.6alkanoylamino, nitro, carboxy, carbamoyl, N-(d.6alkyl)carbamoyl, N,N- (d-6alkyl)2carbamoyl, d^alkoxycarbonyl, mercapto, d_6alkylsulphanyl, d-6alkylsulphinyl, Cι.6alkylsulphonyl, sulphamoyl, N-(d_6alkyl) sulphamoyl or NN-(C1.6alkyl)2sulphamoyl, wherein two such adjacent groups may join to form a 6-membered saturated, partially saturated or unsaturated ring; Het is a fully saturated monocyclic 5 - 8 membered heterocyclic ring, with up to 4 ring heteroatoms; and, R3 is H or d_6alkyl; or a pharmaceutically acceptable salt thereof; provided that when R1, R2 and R3 are all hydrogen then Ar is not 4-chlorophenyl. Preferred values for Ar, R , R and R are as follows. Preferably Ar is optionally substituted phenyl or optionally substituted naphthyl said optional substituents being chosen from one or more of halo and d.6alkyl.
More preferably Ar is phenyl substituted with 1 to 3 chloro or methyl moieties, or naphthyl substituted with 1 bromo group. Particularly Ar is phenyl substituted with 2 chloro groups or naphthyl substituted with
1 bromo group.
More particularly Ar is 2,6-dichlorophenyl or l-bromo-napth-2-yl.
Preferably R1 is hydrogen.
Preferably R2 is hydrogen, d_6alkoxy (optionally substituted with one or more C2. alkynyl, R4, R4C2.6alkenyl, R4C2.6alkynyl or Het), d-6alkanoylamino, trifluoromethoxy, d_6alkylsulphanyl or R4 wherein R4 is optionally substituted phenyl or an optionally substituted 5 or 6 membered heteroaryl ring said optional substituents being chosen from one or more d.6alkyl groups. Het is as defined above (that is it is: a fully saturated monocyclic 5 - 8 membered heterocyclic ring, with up to 4 ring heteroatoms; for example pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidyl, piperazinyl or morpholinyl).
For example R2 is hydrogen, d.6 alkoxy (optionally substituted with one or more halogen, C2.6 alkynyl, R4, R4C2.6 alkenyl, R4C2.6 alkynyl or Het), d_6 alkanoylamino, Cι-6 alkylsulphanyl or R4; R4 is optionally substituted phenyl or an optionally substituted 5 or 6 membered heteroaryl ring said optional substituents being chosen from one or more Cj.6 alkyl groups, wherein two such adjacent groups may join to form a 6-membered saturated, partially saturated or unsaturated ring; Het is a fully saturated monocyclic 5 - 8 membered heterocyclic ring, with up to 4 ring heteroatoms. For example R4 is optionally substituted: phenyl, pyridyl, triazolyl, pyrazolyl, furyl or thienyl. For example Het is pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidyl, piperazinyl or morpholinyl. More preferably R2 is hydrogen, methoxy, ethoxy, propoxy, 3-phenylprop-2-ynyloxy,
3-phenylprop-2-enyloxy, 2-morpholinoethoxy, acetamido, trifluoromethoxy, methylthio, ethylthio, propylthio, 2-propynyloxy, pyridylmethoxy, optionally substituted pyrazolyl, optionally substituted triazolyl, optionally substituted furyl, optionally substituted thienyl where said optional substituents are chosen from 1 or 2 methyl groups. In another aspect the present invention provides a compound of formula (I) wherein R2 is hydrogen, methoxy, ethoxy, propoxy, 3-phenylprop-2-ynyloxy, 3-phenylprop-2-enyloxy, 2-morpholinoethoxy, acetamido, 2,2,2-trifluoroethoxy, methylthio, ethylthio, wo-propylthio, 2-propynyloxy, pyridylmethoxy, optionally substituted pyrazolyl, optionally substituted triazolyl, optionally substituted furyl, optionally substituted thienyl where said optional substituents are chosen from 1 or 2 methyl groups or said 5-membered ring is fused to a benzene ring (to form, for example, a benzotriazolyl bicyclic ring system).
Particularly R2 is methoxy, ethoxy, π-propoxy, 2-morpholinoethoxy, 2-propynyloxy and isopropylthio. Preferably R3 is hydrogen.
According to another aspect of the present invention there is provided a compound of the formula (I) wherein:
Ar is optionally substituted phenyl or optionally substituted naphthyl said optional substituents being chosen from one or more of halo and d_ alkyl; R1 is hydrogen;
R2 is hydrogen, d_6alkoxy (optionally substituted with C2_6alkynyl, R4C2.6alkenyl, R4C2.6alkynyl or Het), d.6alkanoylamino, trifluoromethoxy, Cj-6alkylsulphanyl or R4 wherein R4 is optionally substituted phenyl or an optionally substituted 5 or 6 membered heteroaryl ring said optional substituents being chosen from one or more d_6alkyl groups; and R is hydrogen; or a pharmaceutically acceptable salt thereof. Het is as defined above (that is it is: a fully saturated monocyclic 5 - 8 membered heterocyclic ring, with up to 4 ring heteroatoms; for example pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidyl, piperazinyl or morpholinyl).
A further preferred class of compounds is that of formula (I) wherein: Ar is phenyl substituted with 2 chloro groups or naphthyl substituted with 1 bromo group;
R1 is hydrogen;
R is methoxy, ethoxy, n-propoxy, 2-morpholinoethoxy, 2-propynyloxy or isopropylthio; and R3 is hydrogen; or a pharmaceutically acceptable salt thereof.
In a further aspect the present invention provides a compound of formula (I) wherein Ar is phenyl optionally substituted with halogen (such as chlorine) or CM alkyl (such as methyl), or naphthyl optionally substituted by halogen (such as bromo); R1 and R3 are both hydrogen; and R2 is hydrogen, d-6 alkoxy (optionally substituted by halogen (such as fluorine), pyridinyl or morpholinyl), d-6 alkylthio, C2.6 alkenyloxy (optionally substituted by phenyl), C2.6 alkynyloxy (optionally substituted by phenyl), d_4 alkylcarbonylamino or optionally substituted 5 membered heteroaryl (such as thienyl, furyl (itself optionally substituted by d.4 alkyl), pyrazolyl (itself optionally substituted by Cj. alkyl) or benzotriazolyl); or a pharmaceutically acceptable salt thereof.
Preferred compounds are those of Examples 1 - 26 or a pharmaceutically acceptable salt thereof.
In a further aspect the present invention provides a compound of formula (I) wherein Ar is phenyl disubstituted with halogen (such as chlorine), or naphthyl monosubstituted by halogen (such as bromo); R and R are both hydrogen; and R is Cj.6 alkoxy (optionally substituted by morpholinyl), d_6 alkylthio or C2.6 alkynyloxy; or a pharmaceutically acceptable salt. Thus, R2 is, for example, methoxy, ethoxy, n-propoxy, .sø-propylthio, 2- propynyloxy or 2-morpholinoethoxy.
Especially preferred compounds are those of Examples 1, 3, 5, 8, 10, 16 or 19 or a pharmaceutically acceptable salt thereof.
Suitable pharmaceutically acceptable salts include acid addition salts such as the methanesulphonate, fumarate, hydrochloride, hydrobromide, citrate and maleate salts and salts formed with phosphoric and sulphuric acid. In another aspect suitable salts are base salts such as an alkali metal salt for example a sodium salt, an alkaline earth metal salt for example a calcium or a magnesium salt, an organic amine salt for example a salt with triethylamine, morpholine, N-methylpiperidine, N-ethylpiperidine, procaine, dibenzylamine, NN-dibenzylethylamine or an amino acid for example a lysine salt. There may be more than one cation or anion depending on the number of charged functions and the valency of the cations or anions. A preferred pharmaceutically acceptable salt is a sodium salt. Some compounds of formula (I) may possess chiral centres. It is to be understood that the invention encompasses all such optical isomers and diasteroisomers of compounds of formula (I) which possess cysteine protease inhibitory activity.
The invention further relates to all tautomeric forms of the compounds of formula (I). It is also to be understood that certain compounds of the formula (I) can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms.
Another aspect of the present invention provides a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof. According to this aspect of the invention there is provided a process (in which variable groups are as defined for formula (I) unless otherwise stated) which comprises:
a) reacting an amine of formula (II)
(II) with an acid of formula (III)
O
Ar OH (III) or a reactive derivative thereof. A suitable reactive derivative of an acid of the formula (II) is, for example, an acyl halide, for example an acyl chloride formed by the reaction of the acid and an inorganic acid chloride, for example thionyl chloride; a mixed anhydride, for example an anhydride formed by the reaction of the acid and a chloroformate such as isobutyl chloroformate; an active ester, for example an ester formed by the reaction of the acid and a phenol such as pentafluorophenol, an ester such as pentafluorophenyl trifluoroacetate, an alcohol such as 1- hydroxybenzotriazole or a uronium salt such as 2-(l-benzotriazolyl)-l, 1,3,3- tetramethyluronium hexafluorophosphate(V); an acyl azide, for example an azide formed by the reaction of the acid and an azide such as diphenylphosphoryl azide; an acyl cyanide, for example a cyanide formed by the reaction of an acid and a cyanide such as diethylphosphoryl cyanide; or the product of the reaction of the acid and a carbodiimide such as N,N- dicyclohexylcarbodiimide or l-(3-dimethylaminopropyl)-3-ethylcarbodiimide.
The reaction is preferably carried out in the presence of a suitable base such as, for example, an alkali or alkaline earth metal carbonate, alkoxide or hydroxide, for example sodium carbonate or potassium carbonate, or, for example, an organic amine base such as, for example, pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine or diazabicyclo-[5.4.0]undec-7-ene. The reaction is also preferably carried out in a suitable inert solvent or diluent, for example methylene chloride, acetonitrile, tetrahydrofuran, 1 ,2- dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-one or dimethylsulphoxide, and at a temperature in the range, for example, -78° to 150°C, conveniently at or near ambient temperature. b) dehydration of an amide of formula (IV)
Figure imgf000014_0001
(IV) under standard conditions.
For example such a dehydration reaction may conventionally be carried out by reaction with a reagent such as trifluoroacetic anhydride. The reaction can conveniently be conducted in the presence of a suitable base as defined hereinbefore such as, for example, triethylamine. The reaction is also preferably carried out in a suitable inert solvent or diluent, as defined hereinbefore such as dichloromethane and at a temperature in the range, for example, -10°C to reflux conveniently 10°C to reflux. If not commercially available, the necessary starting materials for the procedures described above may be made by procedures which are selected from standard organic chemical techniques, techniques which are analogous to the synthesis of known, structurally similar compounds, by techniques which are analogous to the above described procedures or by techniques which are analogous to the procedures described in the examples.
For example, it will be appreciated that certain of the optional substituents on a phenyl or naphthyl or a heteroaryl ring in the compounds of the present invention may be introduced by standard aromatic substitution reactions or generated by conventional functional group modifications either prior to or immediately following the processes mentioned above, and as such are included in the process aspect of the invention. Such reactions and modifications include, for example, introduction of a substituent by means of an aromatic substitution reaction, reduction of substituents, alkylation of substituents and oxidation of substituents. The reagents and reaction conditions for such procedures are well known in the chemical art.
Particular examples of aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and a Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halogeno group.
Particular examples of modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl. It will also be appreciated that in some of the reactions mentioned herein it may be necessary/desirable to protect any sensitive groups in the compounds. The instances where protection is necessary or desirable and suitable methods for protection are known to those skilled in the art. Thus, if reactants include groups such as amino, carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned herein. A suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or t-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a t-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine. A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a t-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
The protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.
Many of the intermediates defined herein are novel, for example, those of the formula (IV) and these are provided as a further feature of the invention.
According to a further feature of the invention there is provided a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for use in a method of treatment of the human or animal body by therapy. According to a further feature of the present invention there is provided a method for producing inhibition of a cysteine protease in a warm blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof. The invention also provides a compound of the formula wherein Ar is (optionally substituted phenylC1.6alkyl)2CH-, substituted phenyl (but not phenyl substituted only with nitro) or optionally substituted naphthyl, said optional substituents being chosen from one or more of halo, d.6alkoxy, d-6alkyl, nitro, d. alkanoylamino, trifluoromethyl, hydroxy, trifluoromethoxy, cyano, d_6alkanoyl, d-6alkanoyloxy, amino, Cι_6alkylamino, (d.6alkyl)2amino, carboxy, carbamoyl, N-(Cι_6alkyl)carbamoyl, N,N-(Cι_6alkyl) carbamoyl, Ci.6alkoxycarbonyl, mercapto, d-6alkylsulphanyl, d-6alkylsulphinyl, Cj.6alkylsulphonyl, sulphamoyl, N-(d_6alkyl)sulphamoyl, N,N-(C1.6alkyl)2sulphamoyl, aminoC^όalkyl, ΛMCι-6alkyl)aminoCι-6alkyl, (d.6alkyl)2aminod-6alkyl, R5S-, R5C(O)- or R5CH2-; R5 is phenyl which is optionally substituted by one or more groups chosen from d_6alkyl, halo, trifluoromethyl, hydroxy, trifluoromethoxy, cyano, d-6alkoxy, Cμ6alkanoyl, d.6alkanoyloxy, amino, Cι_6alkylamino, (C1.6alkyl)2amino,
Figure imgf000017_0001
nitro, carboxy, carbamoyl, N-(d_6alkyl)carbamoyl, N,N-(d_6alkyl) carbamoyl, C1.6alkoxycarbonyl, mercapto, d_6alkylsulphanyl, d-6alkylsulphinyl, d-6alkylsulphonyl, sulphamoyl, N-(Cι.6alkyl)sulphamoyl or N,N-(d_6alkyl)2sulphamoyl; R1 is H or d.6alkyl; R2 is H, d_6alkyl (optionally substituted with one or more hydroxy, Cι„6alkylsulphanyl,
Cι.6alkylsulphinyl, d-6alkylsulphonyl, R4, R4C1.6alkylsulphanyl, R Cμ6alkylsulphinyl or R4C].6alkylsulphonyl), d_6alkoxy (optionally substituted with one or more halogen, C2.6alkenyl, C2.6alkynyl, R4, R4C .6alkenyl, R4C2.6alkynyl or Het), C2_6alkenyl, C2-6alkynyl, d_6 alkoxycarbonyl, carbamoyl, N-(Cι-6alkyl)carbamoyl, N,N-(C1.6alkyl)2carbamoyl, R4-, R4S-, R4Cι.6alkylsulphanyl, N-(R4d.6alkyl)carbamoyl, N-(Hetd.6alkyl)carbamoyl, Ci-όalkanoylamino, Cι_6alkylsulphanyl, d.6alkylsulphinyl or d_6alkylsulphonyl; R4 is optionally substituted phenyl, or an optionally substituted 5 or 6 membered heteroaryl ring, said optional substituents on R4 being chosen from one or more of d.6alkyl, halo, trifluoromethyl, hydroxy, trifluoromethoxy, cyano, d-6alkoxy, d-βalkanoyl, d.6alkanoyloxy, amino, d.6alkylamino, (C1.6alkyl)2amino, Ci-όalkanoylamino, nitro, carboxy, carbamoyl, N-(Cι_6alkyl)carbamoyl, N,N-(d.6alkyl)2carbamoyl, Cι_6alkoxycarbonyl, mercapto, Cι.6alkylsulphanyl, d_6alkylsulphinyl, d.6alkylsulphonyl, sulphamoyl, N-(d.6alkyl)sulphamoyl or N,N-(d.6alkyl)2sulphamoyl, wherein two such adjacent groups may join to form a 6-membered saturated, partially saturated or unsaturated ring; Het is a fully saturated monocyclic 5 - 8 membered heterocyclic ring, with up to 4 ring heteroatoms; and, R3 is H or Cι_6alkyl; or a pharmaceutically acceptable salt thereof; for use as a medicament.
In another aspect the present invention provides the use of a compound of the formula (I), wherein Ar is (optionally substituted phenylC1_6alkyl)2CH-, optionally substituted phenyl, optionally substituted naphthyl or an optionally substituted heteroaryl ring, said optional substituents being chosen from one or more of halo,
Figure imgf000018_0001
Cj.6alkyl, nitro, Cι_ alkanoylamino, trifluoromethyl, hydroxy, trifluoromethoxy, cyano, Cι_6alkanoyl, d_6alkanoyloxy, amino, d_6alkylamino, (C1.6alkyl)2amino, carboxy, carbamoyl, N-(d. alkyl)carbamoyl, N,N-(C1.6alkyl)2carbamoyl, d-6alkoxycarbonyl, mercapto, d-6alkylsulphanyl, d-6alkylsulphinyl, d^alkylsulphonyl, sulphamoyl, N-(d-6alkyl)sulphamoyl, NN-(d- alkyl)2sulphamoyl, aminoCι_6alkyl,
N-(Cι.6alkyl)aminod.6alkyl, (Cι.6alkyl)2aminoCι.6alkyl, R5S-, R5C(O)- or R5CH2-; R5 is phenyl which is optionally substituted by one or more groups chosen from Cι.6alkyl, halo, trifluoromethyl, hydroxy, trifluoromethoxy, cyano, Cι_6alkoxy, Cι-6alkanoyl, d_6alkanoyloxy, amino, d_6alkylamino, (C1.6alkyl)2amino, d.6alkanoylamino, nitro, carboxy, carbamoyl, N-(C].6alkyl)carbamoyl, N,N-(Cj.6alkyl)2carbamoyl, d_6alkoxycarbonyl, mercapto, Cι.6alkylsulphanyl, Cι_6alkylsulphinyl, Cι.6alkylsulphonyl, sulphamoyl, N-(Cι.6alkyl)sulphamoyl or N,N-(Cι-6alkyl)2sulphamoyl; R1 is H or d^alkyl; R2 is H, d_6alkyl (optionally substituted with one or more hydroxy, d-βalkylsulphanyl,
Figure imgf000018_0002
Cι.6alkylsulphonyl, R4, R4C1.6alkylsulphanyl, R4d.6alkylsulphinyl or R4d_ alkylsulphonyl), d_6alkoxy (optionally substituted with one or more halogen,
C2_6alkenyl, C2.6alkynyl, R4, R4C2.6alkenyl, R4C2.6alkynyl or Het), C2.6alkenyl, C2_6alkynyl, Cj.6 alkoxycarbonyl, carbamoyl, N-(d-6alkyl)carbamoyl, N,N-(C1.6alkyl)2carbamoyl, R4-, R S-, R4d.6alkylsulphanyl, N-(R4d.6alkyl)carbamoyl, N-(HetC!.6alkyl)carbamoyl, Cμealkanoylamino, d. alkylsulphanyl, d.6alkylsulphinyl or Cι_6alkylsulphonyl; R4 is optionally substituted phenyl, or an optionally substituted 5 or 6 membered heteroaryl ring, said optional substituents on R4 being chosen from one or more of d- alkyl, halo, trifluoromethyl, hydroxy, trifluoromethoxy, cyano, d^alkoxy, d.6alkanoyl, d.6alkanoyloxy, amino, Cι_6alkylamino, (d-6alkyl) amino, d-βalkanoylamino, nitro, carboxy, carbamoyl, N-(Cι-6alkyl)carbamoyl, N,N-(C1.6alkyl)2carbamoyl, d.6alkoxycarbonyl, mercapto, Cι-6alkylsulphanyl, d-6alkylsulphinyl, d-6alkylsulphonyl, sulphamoyl,
N-(C].6alkyl)sulphamoyl or N,N-(C1.6alkyl)2sulphamoyl, wherein two such adjacent groups may join to form a 6-membered saturated, partially saturated or unsaturated ring; Het is a fully saturated monocyclic 5 - 8 membered heterocyclic ring, with up to 4 ring heteroatoms; and, R3 is H or d.6alkyl; or a pharmaceutically acceptable salt thereof; in the manufacture of a medicament for use in the inhibition of a cysteine protease in a warm blooded animal, such as man.
The invention further provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of chronic obstructive pulmonary disease (COPD) in a warm blooded animal, such as man.
In particular the invention provides the use of a compound of the formula (I) of the present invention, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the inhibition of Cathepsin S in a warm blooded animal, such as man.
The invention also provides the use of a compound of the formula (I) of the present invention, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the inhibition of Cathepsin L in a warm blooded animal, such as man.
The present invention further provides a method of treating a Cathepsin L or Cathepsin S mediated disease state in mammals which comprises administering to a mammal in need of such treatment an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.
In order to use a compound of the formula (I) or a pharmaceutically acceptable salt thereof for the therapeutic treatment of mammals including humans, in particular in the inhibition of a cysteine protease, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition. Therefore in another aspect the present invention provides a pharmaceutical composition which comprises a compound of the formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent or carrier.
The pharmaceutical compositions of this invention may be administered in standard manner for the disease condition that it is desired to treat, for example by oral, rectal or parenteral administration. For these purposes the compounds of this invention may be formulated by means known in the art into the form of, for example, tablets, capsules, aqueous or oily solutions or suspensions, (lipid) emulsions, dispersible powders, suppositories, ointments, creams, drops and sterile injectable aqueous or oily solutions or suspensions. A suitable pharmaceutical composition of this invention is one suitable for oral administration in unit dosage form, for example a tablet or capsule which contains between 100 mg and 1 g of the compound of this invention.
In another aspect a pharmaceutical composition of the invention is one suitable for intravenous, subcutaneous or intramuscular injection. Each patient may receive, for example, an intravenous, subcutaneous or intramuscular dose of 1 mgkg 1 to 100 mgkg"1 of the compound, preferably in the range of 5 mgkg"1 to 20 mgkg"1 of this invention, the composition being administered 1 to 4 times per day. The intravenous, subcutaneous and intramuscular dose may be given by means of a bolus injection. Alternatively the intravenous dose may be given by continuous infusion over a period of time. Alternatively each patient will receive a daily oral dose which is approximately equivalent to the daily parenteral dose, the composition being administered 1 to 4 times per day.
The following illustrate representative pharmaceutical dosage forms containing the compound of formula (I), or a pharmaceutically-acceptable salt thereof (hereafter compound X), for therapeutic or prophylactic use in humans: (a)
Figure imgf000021_0001
( )
Figure imgf000022_0001
Buffers, pharmaceutically-acceptable cosolvents such as polyethylene glycol, polypropylene glycol, glycerol or ethanol or complexing agents such as hydroxy-propyl β cyclodextrin may be used to aid formulation. Note
The above formulations may be obtained by conventional procedures well known in the pharmaceutical art. The tablets (a)-(c) may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate.
Inhibition of Cathepsin L and S.
The pharmaceutically-acceptable compounds of the present invention are useful in the inhibition of Cathepsin L and Cathepsin S, having a good activity in vitro against human Cathepsin L, human Cathepsin S and rabbit Cathepsin L.
Cathepsin L Assay
Recombinant human Cathepsin L was cloned and expressed in E Coli and purified using the method as described by Zeneca Limited, GB 2 306 961 A (published 14.05.1997).
Rabbit Cathepsin L was purified from rabbit liver as described by Maciewicz R. A. and Etherington D. J. (Biochem. J. (1988) 256, 433-440) except the liver homogenate supernatant was concentrated by fractionation with (NHU)2SO (20-80% saturation), and the pellet taken up and dialysed against 20mM NaAcetate pH 5.5, ImM ethylenediaminetetraacetic acid (EDTA). The supernatant was then applied to a CM Sepharose ion exchange column and Cathepsin L eluted by gradient elution (0.25-0.75M NaCl). Fraction activity was determined using the 5 synthetic substrate NCBz-Phe-Arg-NHMec as described. Cathepsin L fractions were pooled and desalted on a Sephacryl SI 00 column. Active fractions were pooled, adjusted to 20% saturation (NH4)2SO4 and concentrated on a phenyl sepharose column. The remaining purification steps were as described.
Cathepsin L activity was measured based on the method of Barrett and Kirschke (1981
10 Methods in Enzymology, 80, 535-561), using the fluorogenic substrates NCBz-Phe-Arg- NHMec. Inhibitors were identified by their ability to decrease the generation of the fluorescent leaving group (NHMec). Briefly the assay was as follows: rHuman Cathepsin L or rabbit Cathepsin L (0.025 pmoles) was pre-incubated with or without test compound in 0.1M sodium acetate buffer pH4.5, lOmM cysteine, 0.1% Brij 35 at
15 25°C for 15 minutes in a solid black 96 well plate. Synthetic substrate, 20μM NCBz-Phe-Arg- NHMec, was added and the mixture incubated at 37°C for 30 minutes. The reaction was stopped by the addition of 0.1M sodium chloroacetate pH 4.3. Fluorescence was determined using a Fluoroskan II plate reader; excitation 355nm, emission 460nm. Compound potency was determined from the raw fluorescence data by calculating the IC50 against each enzyme 0 using a PC graph drawing software package. Cathepsin S assay. Cloning and Expression of human Cathepsin S.
Recombinant human Cathepsin S was cloned and expressed in Baculovirus, by the following method. The cDNA sequence for human Cathepsin S is available in the EMBL
25 database Accession Number M90696. This database sequence was used to prepare, by PCR on mRNA from human tissues, a recombinant plasmid carrying an insert with a DNA sequence identical to that of Cathepsin S in the EMBL database (Ace No M90696). The techniques for mRNA isolation, PCR and cloning are standard techniques known by those skilled in the art. Sequence determination of the recombinant insert was carried out using established DNA
30 sequencing techniques. The PCR was done so as to introduce an EcoRI cloning site 5' of the 'ATG' of Cathepsin S and an Xbal cloning site 3' of the 'Stop' codon. The PCR product was cloned between the EcoRI and Xbal sites of the baculovirus transfer vector pFASTBAC-1 (Bac-to- Bac Expression System commercially available from Gibco BRL -Life Technologies ( cat no 5 10359-016)). This recombinant construct was used to generate, by standard techniques, a recombinant baculovirus capable of expressing preprocathepsin S.
Expression of recombinant Cathepsin S was tested for the baculoviral constructs by infection of two insect cell lines : Sf9 cells (ATCC No CRL-1711) and T.ni cells (Invitrogen, Cat No B855-02). 10 Purification of Cathepsin S Method 1.
Procathepsin S was found in the insect cell medium and acid activated. The medium was mixed with an equal volume of lOOmM Sodium Acetate buffer pH 4.5, 5mM dithiothreitol (DTT) and 5mM EDTA and incubated for one hour at 37°C method of Maubach 15 et al (Eur. J. Biochem., 250, 745-750, 1997).
Method 2.
The pH of insect cell medium (10ml) containing procathepsin S was adjusted to 4.5 with glacial acetic acid and DTT and EDTA added to 5mM. The sample was then incubated at
20 37°C for 150min to enable conversion to the active enzyme. Ammonium sulphate was then added to 80% saturation and a pellet obtained by centrifugation. This pellet was redissolved in 2ml buffer A (lOOmM Tris, 500mM NaCl, ImM EDTA, pH7.5) and mixed in a batchwise fashion with lOOμl thiopropyl-Sepharose for 15min at 4°C. The non bound fraction was removed by a brief centrifugation and the gel washed with 2x1 ml buffer A. Cathepsin S was
25 then eluted by batch mixing with 0.4ml 20mM DTT in buffer A for 15min at 4°C.
Measurement of Cathepsin S Activity.
Cathepsin S activity was measured based on the method of Maubach et al (Eur. J. Biochem., 250, 745-750, 1997), using the fluorogenic substrate Z-Nal-Val-Arg-NHMec. Inhibitors were identified by their ability to decrease the generation of the fluorescent leaving group (NHMec). Briefly the assay was as follows: rHuman Cathepsin S (1.5 nmoles) was pre-incubated with or without compounds in 50mM Potassium phosphate buffer pH 6.0-6.2, 20mM Na2EDTA, 0.1% Brij at 25°C for 5 minutes in a solid black 96 well plate. Synthetic substrate, 20μM Z-Val-Val-Arg-NHMec, was added and the mixture incubated at 30°C for 20 minutes. The reaction was stopped by the addition of 0.1M sodium chloroacetate pH 4.3. Fluorescence was determined using a Fluoroskan II plate reader; excitation 355nm, emission 460nm. Compound potency was determined from the raw fluorescence data by calculating the IC50 against Cathepsin S using a PC graph drawing software package.
The following results were obtained on a standard in-vitro test system for the inhibition of Cathepsin L. The activity is described in terms of IC50.
When tested in the above in-vitro tests the compounds of this invention give IC50S in the range 1-10,000 nM. The following data was obtained for Examples 5, 14 and 23.
Figure imgf000025_0001
Examples
The invention will now be illustrated by the following non-limiting examples in which, unless stated otherwise:
(i) temperatures are given in degrees Celsius (°C); operations were carried out at room or ambient temperature, that is, at a temperature in the range of 18-25°C; (ii) organic solutions were dried over anhydrous magnesium sulphate; evaporation of solvent was carried out using a rotary evaporator under reduced pressure (600-4000 Pascals; 4.5-30 mm Hg) with a bath temperature of up to 60°C;
(iii) chromatography means flash chromatography on silica gel; thin layer chromatography (TLC) was carried out on silica gel plates;
(iv) in general, the course of reactions was followed by TLC and reaction times are given for illustration only;
(v) final products had satisfactory proton nuclear magnetic resonance (NMR) spectra; (vi) yields are given for illustration only and are not necessarily those which can be obtained by diligent process development; preparations were repeated if more material was required; (vii) when given, NMR data is in the form of delta values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard, determined at 250 MHz using perdeuterio dimethyl sulphoxide (DMSO-δ6) as the solvent unless otherwise stated;
(viii) chemical symbols have their usual meanings; SI units and symbols are used;
(ix) solvent ratios are given in percentage by volume;
(x) mass spectra (MS) were run with an electron energy of 70 electron volts in the chemical ionisation (CI) mode using a direct exposure probe; where indicated ionisation was effected by electron impact (El) or fast atom bombardment (FAB); where values for m/z are given, generally only ions which indicate the parent mass are reported; and
(xi) melting points are uncorrected and (dec) indicates decomposition; the melting points given are those obtained for the materials prepared as described; polymorphism may result in isolation of materials with different melting points in some preparations.
Example 1 2-(2,6-Dichlorobenzamido)-2-propoxyacetonitrile
Trifluoroacetic anhydride (0.51 ml) was added dropwise to a stirred mixture of 2-(2,6- dichlorobenzamido)-2-propoxyacetamide (360 mg) in pyridine (5 ml) at -10°C. The mixture was allowed to warm to ambient temperature then poured into ice-water and extracted with ether. The organic phase was washed with brine, dried and evaporated to dryness under reduced pressure. The residue was triturated with hexane and the insoluble solid collected to give 2-(2,6-dichlorobenzamido)-2-propoxyacetonitrile (235 mg). Mp 115-117°C; m z 287 (MH+); NMR 0.9 (t, 3H), 1.55 (m, 2H), 3.6 (t, 2H), 6.25 (d, 1H), 7.4-7.6 (m, 3H), 10.35 (d, 1H). Example 2
2-(2 ,6-Dichlorobenzamido)-2-(3 ,5-dimethylpyrazol- 1 -yPacetonitrile
POCl3 (0.34 ml) was added dropwise to stirred ice cooled N,N-dimethylformamide (3 ml) and the mixture was added dropwise to a stirred solution of 2-(2,6-dichlorobenzamido)-2- (3,5-dimethylpyrazol-l-yl)acetamide (500 mg) in N,N-dimethylformamide (4 ml). The solution was stirred at ambient temperature for 0.5 hours then poured into water. The mixture was extracted with ethyl acetate and the extract was dried and evaporated to dryness. The residue was triturated with ether and the insoluble solid collected to give 2-(2,6-dichlorobenzamido)- 2-(3,5-dimethylpyrazol-l-yl)acetonitrile (214 mg). m/z 323 (MH+); ΝMR 2.15 (s, 3H), 2.35 (s, 3H), 5.95 (s, 1H), 7.4-7.55 (m, 4H), 10.7 (d, 1H). Examples 3-15
The compounds listbed in the following table were made by processes analogous to either Example 1 or Example 2.
Figure imgf000027_0001
Figure imgf000027_0002
Figure imgf000028_0001
Ph = phenyl Example 16
2-( 1 -Bromo-2-naphthoylamino)-2-isopropylthioacetonitrile
The process described in Example 2 was repeated using 2-(l-bromo-2- naphthoylamino)-2-isopropylthioacetamide as starting material to give 2-(l-bromo-2- naphthoylamino)-2-isopropylthioacetonitrile. Mp 121-122°C; m/z 363 (MH+) NMR (CDC13) 1.4 (d, 3H), 1.5 (d, 3H), 3.4 (m, IH), 6.25 (d, IH), 6.8 (m, IH), 7.4 (d, IH), 7.65 (m, 2H), 7.85 (m, 2H), 8.35 (d, IH). Example 17 2-(2.4-Dichlorobenzamido)-2-isopropylthioacetonitrile
The process described in Example 2 was repeated using 2-(2,4-dichlorobenzamido)-2- isopropylthioacetamide as starting material to give 2-(2,4-dichlorobenzamido)-2- isopropylthioacetonitrile. Mp 110-111°C; m/z 303 (MH+) NMR (CDC13); 1.35 (d, 3H), 1.45 (d, 3H), 3.35 (m, IH), 6.15 (d, IH), 7.1 (m, IH), 7.35 (dd, IH), 7.45 (d, IH), 7.7 (d, IH). Example 18
2-(2.6-Dichlorobenzamido)-2-isopropylthioacetonitrile
A solution of 2-benzyloxycarbonylamino-2-isopropylthioacetonitrile (450 mg) in dichloromethane (10 ml) was stirred under argon and then treated with iodotrimethylsilane (0.28 ml). The solution was stirred for 0.5 hours then treated with methanol (0.2 ml) and the mixture was evaporated to dryness under reduced pressure. A solution of the residue in dichloromethane (10 ml) was stirred under argon and treated with 2,6-dichlorobenzoyl chloride (420 mg) followed by triethylamine (0.5 ml) and the mixture was stirred at ambient temperature for 18 hours. The mixture was evaporated to dryness under reduced pressure and a solution of the residue in diethyl ether was washed successively with IM hydrochloric acid, IM sodium hydroxide and brine, dried and evaporated to dryness under reduced pressure. The residue was purified by flash chromatography using increasingly polar mixtures of dichloromethane and hexane as eluent followed by recrystallisation from carbon tetrachloride to give 2-(2,6-dichlorobenzamido)-2-isopropylthioacetonitrile (67 mg). M/z 303 (MH+); NMR (CDC13) 1.35 (d, 3H), 1.45 (d, 3H), 3.35 (m, IH), 6.15 (d, IH), 6.4 (m, IH), 7.3-7.4 (m, 3H). Example 19
2-( 1 -Bromo-2-naphthoylamino)-2-methoxyacetonitrile N-bromosuccinimide (70 mg) was added to a stirred solution of 2-(l-bromo-2- naphthoylamino)-2-isopropylthioacetonitrile (120 mg) in methanol (2 ml) at -30°C. The solution was allowed to warm to ambient temperature. It was stirred for 2 hours then treated with water and the mixture was extracted with ethyl acetate. The mixture was washed with brine, dried and evaporated to dryness under reduced pressure and the residue recrystallised from a mixture of diethyl ether and hexane to give 2-(l-bromo-2-naphthoylamino)-2- methoxyacetonitrile (75 mg). Mp 162-164°C; m/z 319 (MH+); ΝMR (CDC13) 3.65 (s, 3H), 6.2 (d, IH), 6.95 (m, IH), 7.5 (d, IH), 7.65 (m, 2H), 7.9 (m, 2H), 8.4 (m, IH). Example 20 2-(2,4-Dichlorobenzamido)-2-methoxyacetonitrile The process described in Example 19 was repeated using 2-(2,4-dichlorobenzamido)-2- isopropylthioacetonitrile as starting material to give 2-(2,4-dichlorobenzamido)-2- methoxyacetonitrile. Mp 105-106°C; m/z 259 (MH+); ΝMR (CDCI3) 3.55 (s, 3H), 6.15 (d, IH), 7.2 (m, IH), 7.4 (dd, IH), 7.5 (d, IH), 7.7 (d, IH). Example 21 2-( 1 -Bromo-2-naphthoylamino)acetonitrile
N,N-Dimethylformamide (0.05 ml) was added to a stirred mixture of l-bromo-2- naphthoic acid (2 g) , dichloromethane (20 ml) and oxalyl chloride ( (0.9 ml) and the mixture was stirred for 1 hour then evaporated to dryness under reduced pressure.
A portion of the acid chloride (270 mg) was added to a stirred, ice cooled mixture of aminoacetonitrile hydrochloride (0.14 g),dichloromethane (20 ml) and triethylamine (0.5 ml) The mixture was stirred at ambient temperature for 18 hours. Water was added and the dichoromethane separated and washed successively with IM hydrochloric acid, IM sodium hydroxide and brine, dried and evaporated to dryness under reduced pressure. The residue was recrystallised from a mixture of ethyl acetate and hexane to give 2-(l-bromo-2- naphthoylamino)acetonitrile. Mp 172-173°C; m/z 289 (MH+); NMR (CDC13) 4.45 (d, 2H), 6.65 (m, IH), 7.5 (d, IH), 7.65 (m, 2H), 7.85 (m, 2H), 8.35 (m, IH). Example 22 - 25
The following analogues were prepared according to the method of Example 21 using the appropriate benzoic acids and substituted aminoacetonitriles:
Figure imgf000030_0001
Figure imgf000030_0002
Example 26
2-( 1 -Bromo-2-naphthoylamino)-2-(2-thienyl)acetonitrile The process described in Example 21 was repeated using 2-(2-thienyl)-2- aminoacetonitrile instead of aminoacetonitrile to give 2-(l-bromo-2-naphthoylamino)-2-(2- thienyl)acetonitrile. Mp 162-163°C; m/z 371 (M+); NMR (CDCI3); 6.55 (d, 2H), 6.7 (m, IH), 7.1 (m, IH), 7.4 (m, 2H), 7.5 (d, IH), 7.65 (m, 2H), 7.85 (m, 2H), 8.35 (m, IH).
Preparation of Starting Materials
The starting materials for the Examples above are either commercially available or are readily prepared by standard methods from known materials. For example the following reactions (Methods A-F) are illustrations but not limitations of the preparation of some of the starting materials used in the above reactions. Method A
2-(2-Furyl)aminoacetonitrile
Ammonium chloride (25 g) was added to a solution of 2-furfuraldehyde (25 g) in diethyl ether (250 ml). A solution of sodium cyanide (17 g) in water (80 ml) was added over 20 minutes. The reaction mixture was stirred at ambient temperature for 14 hours , the aqueous layer was removed and the organic layer was washed twice with saturated aqueous sodium hydrogen carbonate solution (100 ml each time), dried and evaporated to dryness. The residue was dissolved in diethyl ether (250 ml) and cooled to 0 °C. Hydrogen chloride gas was bubbled through the solution keeping the temperature below 10 °C. 2-(2- Furyl)aminoacetonitrile hydrochloride was filtered and dried, yield 33 g. 1H NMR 6.19 (s, IH),
6.56 (m, IH), 6.78 (d, IH), 7.83 (m, IH), 9.83 (broad s, 2H).
Methods Al-3
Following the method outlined in Method A and using the appropriate aldehyde there was prepared: Al 2-[2-(5-methylfuryl)]aminoacetonitrile hydrochloride;
A2 2-(3-furyl)aminoacetonitrile hydrochloride;
A3 2-(2-thienyl)aminoacetonitrile hydrochloride;
Method B
2-(2,6-Dichlorobenzamido)-2-propoxyacetamide A solution of 2,6-dichlorobenzoyl chloride (5 ml) in dichloromethane (5 ml) was added dropwise to a stirred mixture of aminoacetonitrile hydrogen sulphate (5.38 g), dichloromethane (75 ml) and triethylamine (17.5 ml) keeping the temperature below 30°C.
The mixture was stirred at ambient temperature for 16 hours then washed successively with water and brine, dried and evaporated to dryness under reduced pressure. The residue was purified by flash chromatography using 1 % methanol in dichloromethane as eluent to give 2-
(2,6-dichlorobenzamido)acetonitrile (6.26 g). Mp 130-134°C; m z 229 (MH+).
A mixture of 2-(2,6-dichlorobenzamido)acetonitrile (2 g), glacial acetic acid (15 ml) and bromine (0.45 ml) was stirred in a bath at 50°C until the solution had decolourised. The mixture was cooled and the insoluble solid collected and washed with dichloromethane to give 2-(2,6-dichlorobenzamido)-2-bromoacetamide (1.43 g), which was used without further purification.
A mixture of 2-(2,6-dichlorobenzamido)-2-bromoacetamide (700 mg) and n-propanol
(4 ml) was heated at 90°C for 5 min and then evaporated to dryness under reduced pressure. The residue was partitioned between chloroform and aqueous sodium hydrogen carbonate, and the organic phase was dried and evaporated to dryness under reduced pressure to give 2-(2,6- dichlorobenzamido)-2-propoxyacetamide (370 mg). M/z 287 (MH+) which was used without further purification.
Methods B 1-2 Using a process similar to that described in Method C using the appropriate alcohol there was prepared:
Bl 2-(2,6-dichlorobenzamido)-2-ethoxyacetamide. M/z 291 (MH+);
B2 2-(2,6-dichlorobenzamido)-2-methoxyacetamide. M/z 277 (MH+).
Methods B 3-10 By a process similar to that described in preparation of the intermediate for Method C but using tetrahydrofuran as solvent instead of excess alcohol there was prepared:
2-(2,6-dichlorobenzamido)-2-(3-phenylprop-2-ynyloxy)acetamide. M/z 377 (MH+);
2-(2,6-dichlorobenzamido)-2-(3-phenylprop-2-enyloxy)acetamide. M/z 379 (MH+);
2-(2,6-dichlorobenzamido)-2-(2-morpholinoethoxy)acetamide. M/z 376 (MH+); 2-(2,6-dichlorobenzamido)-2-ethylthioacetamide. M/z 307 (MH+);
2-(2,6-dichlorobenzamido)-2-(2-propynyl)oxyacetamide. M/z 300 (M+);
2-(2,6-dichlorobenzamido)-2-methylthioacetamide. M/z 293 (MH+);
2-(2,6-dichlorobenzamido)-2-[(2-pyridyl)methoxy]acetamide. M/z 354 (MH+);
2-(2,6-dichlorobenzamido)-2-(2,2,2-trifluoroethoxy)acetamide. M/z 345 (MH+). Method C
2-(2.6-Dichlorobenzamido)-2-(3,5-dimethylpyrazol-l-yl)acetamide
A mixture of 2-(2,6-dichlorobenzamido)-2-bromoacetamide (500 mg), pyridine (4 ml) and 3,5-dimethylpyrazole (442 mg) was heated at 90°C for 5 min and then cooled and diluted to 60 ml with water. The mixture was extracted with ethyl acetate and the organic phase was washed with water, dried and evaporated to dryness under reduced pressure. The residue was triturated with ether and the insoluble solid collected to give 2-(2,6-dichlorobenzamido)-2- (3,5-dimethylpyrazol-l-yl)acetamide (227 mg). M/z 341 (MH+). Method Cl
Using a process similar to that described in Method C using pyrazole instead of 3,5- dimethylpyrazole there was prepared:
Cl 2-(2,6-dichlorobenzamido)-2-(pyrazol-l-yl)acetamide M/z 313 (MH+).
Method D
2-Benzotriazol- 1 -yl-2-(2.6-dichlorobenzamido)acetamide
A mixture of 2,6-dichlorobenzamide (3 g), ethyl glyoxalate (4 g), benzotriazole (2.8 g), para-toluenesulphonic acid (0.2 g) and toluene (100 ml) was heated at reflux in a flask fitted with a Dean and Stark trap for 5 hours. The mixture was evaporated to dryness under reduced pressure and the residue purified by medium pressure liquid chromatography using 0.5 - 1 % methanol in dichloromethane as eluent to give ethyl 2-benzotriazol-l-yl-2-(2,6- dichlorobenzamido)acetate (1.18 g). Mp 194-195°C; m/z 393 (MH+). A mixture of ethyl 2-benzotriazol-l-yl-2-(2,6-dichlorobenzamido)acetate (350 mg) and a saturated solution of ammonia in ethanol (8 ml) was stirred at 0°C for 0.5 hours then kept at 4°C for 18 hours. The solid which had precipitated was collected to give 2-benzotriazol-l-yl- 2-(2,6-dichlorobenzamido)acetamide (55 mg). M/z 364 (MH+). Method E 2-Acetamido-2-(2.6-dichlorobenzamido)acetamide
The filtrate from the above experiment was evaporated to dryness under reduced pressure and the residue was dissolved in a saturated solution of ammonia in ethanol (8 ml) and the solution was kept at ambient temperature for 60 hours. The solution was evaporated to dryness under reduced pressure, the residue was triturated with ether and the insoluble solid collected to give 2-amino-2-(2,6-dichlorobenzamido)acetamide (148 mg).
A mixture of 2-amino-2-(2,6-dichlorobenzamido)acetamide (120 mg), N,N- dimethylformamide (2 ml) and pentafluorophenylacetate (310 mg) was stirred at ambient temperature for 1 hour. The mixture was treated with water and ethyl acetate and the insoluble solid collected to give 2-acetamido-2-(2,6-dichlorobenzamido)acetamide (87 mg). M/z 304 (MH+). Method F
2-( 1 -Bromo-2-naphthoylaminoy 2-isopropylthioacetamide
A mixture of l-bromo-2-naphthoic acid (1.75 g), dichloromethane (20 ml) and oxalyl chloride (0.9 ml) was stirred while adding NN-dimethylformamide (0.05 ml), the mixture was stirred a further 1 hour and then evaporated to dryness. The residual acid chloride was stirred with concentrated aqueous ammonia at for 1 hour and the insoluble solid was collected and washed with water to give l-bromo-2-naphthoylamide (1.67 g),which was used without further purification.
A mixture of 1 -bromo-2-naphthoylamide (750 mg), glyoxilic acid monohydrate (304 mg) and acetone (5 ml) was stirred at reflux for 3 hours and the resulting solution was evaporated to dryness under reduced pressure. A mixture of the residue, isopropanethiol (0.38 g), dichloroethane (10 ml) and 2-naphthalenesulphonic acid (30 mg) was stirred at reflux for 4 hours and the resulting solution was evaporated to dryness under reduced pressure. A mixture of the residue, methanol (30 ml) and concentrated sulphuric acid (2 ml) was stirred at ambient temperature for 2 hours .The solution was poured into a stirred mixture of ice and saturated sodium bicarbonate solution and the mixture was extracted with diethyl ether.The extracts were washed with brine, dried and evaporated to dryness under reduced pressure and the residue was purified by flash chromatography using increasingly polar mixtures of ethylacetate and hexane as eluent to give ethyl 2-(l-bromo-2-naphthoylamino)-2-isopropylthioacetate (550 mg). M/z 396 (MH+).
A mixture of ethyl 2-(l-bromo-2-naphthoylamino)-2-isopropylthioacetate (520 mg), methanol (10 ml) and concentrated aqueous ammonia was stirred at ambient temperature for 3 hours. The solution was diluted with water and the precipitate collected to give 2-(l-bromo-2- naphthoylamino)-2-isopropylthioacetamide (450 mg). Mp 119-120°C; m/z 381 (MH+). Method FI
By a procedure analogous to the procedure described in Method F and using the appropriate starting materials, there was prepared: FI: 2-(2,4-dichlorobenzamido)-2-isopropylthioacetamide. M/z 321 (MH+).

Claims

1. A compound of formula (I):
Figure imgf000035_0001
(I) wherein Ar is (optionally substituted phenylC1.6alkyl)2CH-, optionally substituted phenyl, optionally substituted naphthyl or an optionally substituted heteroaryl ring, said optional substituents being chosen from one or more of halo, d.6alkoxy, d_6alkyl, nitro, Cι_ alkanoylamino, trifluoromethyl, hydroxy, trifluoromethoxy, cyano, d-6alkanoyl, d„6alkanoyloxy, amino, d.6alkylamino, (C1.6alkyl)2amino, carboxy, carbamoyl, N-(d.6alkyl)carbamoyl, N,N-(C1.6alkyl)2carbamoyl, C1.6alkoxycarbonyl, mercapto, d-βalkylsulphanyl, d-6alkylsulphinyl, d.6alkylsulphonyl, sulphamoyl,
Figure imgf000035_0002
N,N-(d.6alkyl)2sulphamoyl, aminod-6alkyl, N-(Cι.6alkyl)aminoCι.6alkyl, (d-ealkyl aminod-ealkyl, R5S-, R5C(O)- or R5CH2-; R5 is phenyl which is optionally substituted by one or more groups chosen from Cι.6alkyl, halo, trifluoromethyl, hydroxy, trifluoromethoxy, cyano, d.6alkoxy, d_6alkanoyl, Cι_6alkanoyloxy, amino, d. alkylamino, (C1.6alkyl)2amino, d.6alkanoylamino, nitro, carboxy, carbamoyl, N-(d-6alkyl)carbamoyl, N,N-(C1-6alkyl)2carbamoyl, Ci-6alkoxycarbonyl, mercapto, d.6alkylsulphanyl, d.6alkylsulphinyl, C].6alkylsulphonyl, sulphamoyl, N-(Cι.6alkyl)sulphamoyl or
N,N-(d.6alkyl)2sulphamoyl; R1 is H or d-6alkyl; R2 is H, d-6alkyl (optionally substituted with one or more hydroxy, Cj.6alkylsulphanyl, d^alkylsulphinyl, d-6alkylsulphonyl, R4, R4C1_6alkylsulphanyl, R4Cι_6alkylsulphinyl or R^i^alkylsulphonyl), Cj.6alkoxy (optionally substituted with one or more halogen, C2.6alkenyl, C2.6alkynyl, R4, R4C2.6alkenyl, R4C2.6alkynyl or Het), C2.6alkenyl,
C2.6alkynyl, CL6 alkoxycarbonyl, carbamoyl,
Figure imgf000035_0003
N,N-(d.6alkyl)2carbamoyl, R4-, R4S-, R4d.6alkylsulphanyl, N-(R4d.6alkyl)carbamoyl, N-(Hetd_6alkyl)carbamoyl, d-βalkanoylamino, d.6alkylsulphanyl, Cj-βalkylsulphinyl or Cj.6alkylsulphonyl; R4 is optionally substituted phenyl, or an optionally substituted 5 or 6 membered heteroaryl ring, said optional substituents on R4 being chosen from one or more of d_ alkyl, halo, trifluoromethyl, hydroxy, trifluoromethoxy, cyano, d.6alkoxy, d.6alkanoyl, Ci-βalkanoyloxy, amino, d.6alkylamino, (C1.6alkyl)2amino, d-6alkanoylamino, nitro, carboxy, carbamoyl, N-(Cι.6alkyl)carbamoyl, N,N-
(Cι.6alkyl)2carbamoyl, d-ealkoxycarbonyl, mercapto, d.6alkylsulphanyl, d.6alkylsulphinyl, d-6alkylsulphonyl, sulphamoyl, N-(Cι-6alkyl)sulphamoyl or N,N-(Cι-6alkyl) sulphamoyl, wherein two such adjacent groups may join to form a 6- membered saturated, partially saturated or unsaturated ring; Het is a fully saturated monocyclic 5 - 8 membered heterocyclic ring, with up to 4 ring heteroatoms; and, R3 is
H or d-6alkyl; or a pharmaceutically acceptable salt thereof.
A compound of formula (I):
Figure imgf000036_0001
(I) wherein Ar is phenyl substituted with 1 to 3 chloro or methyl moieties, or naphthyl substituted with 1 bromo atom; R1 is H or d_6alkyl; R2 is H, d_6alkyl (optionally substituted with one or more hydroxy, Cι-6alkylsulphanyl, d.6alkylsulphinyl, d.6alkylsulphonyl, R4, R4Cι-6alkylsulphanyl, R4d-6alkylsu-phinyl or R4Cι_ alkylsulphonyl), d.6alkoxy (optionally substituted with one or more halogen,
C2.6alkenyl, C .6alkynyl, R4, R4C2.6alkenyl, R4C2.6alkynyl or Het), C2.6alkenyl, C2.6alkynyl, d-6 alkoxycarbonyl, carbamoyl, N-(d.6alkyl)carbamoyl, N,N-(d.6alkyl)2carbamoyl, R4-, R4S-, R4d.6alkylsulphanyl, N-(R4d.6alkyl)carbamoyl, N-(Hetd-6alkyl)carbamoyl, Cι.6alkanoylamino, d.6alkylsulphanyl, d_ alkylsulphinyl or Cι_6alkylsulphonyl; R4 is optionally substituted phenyl, or an optionally substituted 5 or 6 membered heteroaryl ring, said optional substituents on R4 being chosen from one or more of
Figure imgf000036_0002
halo, trifluoromethyl, hydroxy, trifluoromethoxy, cyano, Cι_6alkoxy, d.6alkanoyl, d.6alkanoyloxy, amino, d_6alkylamino, (d.6alkyl)2amino, Cι_6alkanoylamino, nitro, carboxy, carbamoyl, N-(d-6alkyl)carbamoyl, N,N- (d.6alkyl)2carbamoyl, d-6alkoxycarbonyl, mercapto, Cj.6alkylsulphanyl, d.6alkylsulphinyl, d-βalkylsulphonyl, sulphamoyl, N-(d-6alkyl)sulphamoyl or N,N-(d.6alkyl)2sulphamoyl, wherein two such adjacent groups may join to form a 6- membered saturated, partially saturated or unsaturated ring; Het is a fully saturated monocyclic 5 - 8 membered heterocyclic ring, with up to 4 ring heteroatoms; and, R3 is H or d_6alkyl; or a pharmaceutically acceptable salt thereof; provided that when R1, R2 and R3 are all hydrogen then Ar is not 4-chlorophenyl.
3. A compound as claimed in claim 2 wherein R1 is hydrogen.
4. A compound as claimed in claim 2 or 3 wherein R3 is hydrogen.
5. A compound as claimed in claim 2, 3 or 4 wherein R2 is hydrogen, d_6 alkoxy (optionally substituted with one or more halogen, C2.6 alkynyl, R4, R4C .6 alkenyl,
R4C2_6 alkynyl or Het), d_6 alkanoylamino, Cι.6 alkylsulphanyl or R4; R4 is optionally substituted phenyl or an optionally substituted 5 or 6 membered heteroaryl ring said optional substituents being chosen from one or more d_6 alkyl groups, wherein two such adjacent groups may join to form a 6-membered saturated, partially saturated or unsaturated ring; Het is a fully saturated monocyclic 5 - 8 membered heterocyclic ring, with up to 4 ring heteroatoms.
6. A compound as claimed in any one of claims 2 to 5 wherein R2 is hydrogen, methoxy, ethoxy, propoxy, 3-phenylprop-2-ynyloxy, 3-phenylprop-2-enyloxy, 2-morpholinoethoxy, acetamido, 2,2,2-trifluoroethoxy, methylthio, ethylthio, isopropylthio, 2-propynyloxy, pyridylmethoxy, optionally substituted pyrazolyl, optionally substituted triazolyl, optionally substituted furyl, optionally substituted thienyl where said optional substituents are chosen from 1 or 2 methyl groups or said 5-membered ring is fused to a benzene ring (to form, for example, a benzotriazolyl bicyclic ring system).
7. A pharmaceutical composition comprising a compound of formula (I) as claimed in claim 1 or 2 and a pharmaceutically acceptable diluent or carrier.
8. A compound of formula (I):
° R2 R3
I , N
R1
(I) wherein Ar is (optionally substituted phenylCι.6alkyl)2CH-, substituted phenyl (but not phenyl substituted only with nitro) or optionally substituted naphthyl, said optional substituents being chosen from one or more of halo, Cι_6alkoxy, d_6alkyl, nitro,
Cι.6alkanoylamino, trifluoromethyl, hydroxy, trifluoromethoxy, cyano, d.6alkanoyl, Cι_6alkanoyloxy, amino, d_6alkylamino, (d-6alkyl) amino, carboxy, carbamoyl, N-(d_ alkyl)carbamoyl, N,N-(C1_6alkyl)2carbamoyl, d_ alkoxycarbonyl, mercapto, Cι_6alkylsulphanyl, Cμ6alkylsulphinyl, d.6alkylsulphonyl, sulphamoyl, N-(Cι.6alkyl)sulphamoyl, N,N-(C1.6alkyl)2sulphamoyl, aminoCι.6alkyl,
N-(Ci.6alkyl)aminoCi.6alkyl, (C1.6alkyl)2aminoC1.6alkyl, R5S-, R5C(O)- or R5CH2-; R5 is phenyl which is optionally substituted by one or more groups chosen from d.6alkyl, halo, trifluoromethyl, hydroxy, trifluoromethoxy, cyano, d_6alkoxy, d_6alkanoyl, d.6alkanoyloxy, amino, Cι.6alkylamino, (C1.6alkyl)2amino, d-βalkanoylamino, nitro, carboxy, carbamoyl, N-(d_6alkyl)carbamoyl, N,N-(C1.6alkyl)2carbamoyl,
C].6alkoxycarbonyl, mercapto, d.6alkylsulphanyl, d.6alkylsulphinyl, d-6alkylsulphonyl, sulphamoyl, N-(Cι.6alkyl)sulphamoyl or N,N-(C1.6alkyl)2sulphamoyl; R1 is H or d.6alkyl; R2 is H, d-6alkyl (optionally substituted with one or more hydroxy, d.6alkylsulphanyl, d-βalkylsulphinyl, d.6alkylsulphonyl, R4, R4d-6alkylsulphanyl, R4d_6alkylsulphinyl or
R4C].6alkylsulphonyl), Cμealkoxy (optionally substituted with one or more halogen, C2.6alkenyl, C2.6alkynyl, R4, R4C2.6alkenyl, R4C2.6alkynyl or Het), C2_6alkenyl, C . alkynyl, Cι.6 alkoxycarbonyl, carbamoyl, N-(d.6alkyl)carbamoyl, N,N-(d.6alkyl)2carbamoyl, R4-, R4S-, R4d.6alkylsulphanyl, N-(R4C1.6alkyl)carbamoyl, N-(Hetd.6alkyl)carbamoyl, d-ealkanoylamino, d-6alkylsulphanyl, d. alkylsulphinyl or C1.6alkylsulphonyl; R4 is optionally substituted phenyl, or an optionally substituted 5 or 6 membered heteroaryl ring, said optional substituents on R4 being chosen from one or more of d^alkyl, halo, trifluoromethyl, hydroxy, trifluoromethoxy, cyano,
Cι_6alkoxy,
Figure imgf000039_0001
d.6alkanoyloxy, amino, d-6alkylamino, (C1.6alkyl) amino, C).6alkanoylamino, nitro, carboxy, carbamoyl, N-(d-6alkyl)carbamoyl, N,N- (Cι_ alkyl)2carbamoyl, C ^alkoxycarbonyl, mercapto, d.6alkylsulphanyl, d.6alkylsulphinyl, d-βalkylsulphonyl, sulphamoyl, N-(Cι_6alkyl)sulphamoyl or NN-(d.6alkyl)2sulphamoyl, wherein two such adjacent groups may join to form a 6- membered saturated, partially saturated or unsaturated ring; Het is a fully saturated monocyclic 5 - 8 membered heterocyclic ring, with up to 4 ring heteroatoms; and, R3 is H or d-6alkyl; or a pharmaceutically acceptable salt thereof; for use as a medicament.
9. The use of a compound of formula (I) as claimed in claim 1 or 2, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the inhibition of a cysteine protease in a warm blooded animal.
10. The use of a compound of formula (I) as claimed in claim 1 or 2, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of chronic obstructive pulmonary disease in a warm blooded animal.
11. A method of treating a Cathepsin L or Cathepsin S mediated disease state in mammals which comprises administering to a mammal in need of such treatment an effective amount of a compound of formula (I) as claimed in claim 1 or 2, or a pharmaceutically acceptable salt thereof.
12. A process for preparing a compound of formula (I) as claimed in claim 1 or 2, the process comprising: a) reacting an amine of formula (II)
R2 R3 HN i , N
R1
(II) with an acid of formula (III)
Figure imgf000040_0001
(III) or a reactive derivative thereof; or, b) dehydrating an amide of formula (IV)
Figure imgf000040_0002
(IV) under standard conditions; wherein Ar, R1, R2 and R3 are as defined in claim 1.
An intermediate compound of formula (IV) :
Figure imgf000040_0003
(IV) wherein Ar, R , R and R are as defined in claim 1.
PCT/GB2000/000539 1999-02-20 2000-02-16 Acylated aminoacetonitriles as cysteine protease inhibitors WO2000048992A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU25607/00A AU2560700A (en) 1999-02-20 2000-02-16 Acylated aminoacetonitriles as cysteine protease inhibitors
EP00903853A EP1157003A1 (en) 1999-02-20 2000-02-16 Acylated aminoacetonitriles as cysteine protease inhibitors
JP2000599733A JP2002537285A (en) 1999-02-20 2000-02-16 Acylated aminoacetonitriles as cysteine protease inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9903861.4A GB9903861D0 (en) 1999-02-20 1999-02-20 Chemical compounds
GB9903861.4 1999-02-20

Publications (1)

Publication Number Publication Date
WO2000048992A1 true WO2000048992A1 (en) 2000-08-24

Family

ID=10848132

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/000539 WO2000048992A1 (en) 1999-02-20 2000-02-16 Acylated aminoacetonitriles as cysteine protease inhibitors

Country Status (5)

Country Link
EP (1) EP1157003A1 (en)
JP (1) JP2002537285A (en)
AU (1) AU2560700A (en)
GB (1) GB9903861D0 (en)
WO (1) WO2000048992A1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002051983A2 (en) * 2000-12-22 2002-07-04 Axys Pharmaceuticals, Inc. Novel compounds and compositions as cathepsin inhibitors
US6455502B1 (en) 1999-03-15 2002-09-24 Axys Pharmaceuticals, Inc. Compounds and compositions as protease inhibitors
EP1248612A1 (en) * 2000-01-06 2002-10-16 Merck Frosst Canada Inc. Novel compounds and compositions as protease inhibitors
US6977256B2 (en) 2001-11-14 2005-12-20 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin S inhibitors
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
US7196099B2 (en) 2001-09-14 2007-03-27 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
US7342027B2 (en) 2002-07-26 2008-03-11 Yuhan Corporation 1-phenylpiperidin-3-one derivatives and processes for the preparation thereof
EP2251007A2 (en) 2002-09-24 2010-11-17 Novartis AG Sphingosine-1-phosphate (S1P) receptor agonists for use in the treatment of demyelinating diseases
EP2719700A1 (en) 2008-01-09 2014-04-16 Amura Therapeutics Limited Tetrahydrofuro(3,2-b)pyrrol-3-one derivatives as inhibitors of cysteine proteinases
EP3011958A1 (en) 2008-06-20 2016-04-27 Novartis AG Paediatric compositions for treating multiple sclerosis
WO2019197468A1 (en) * 2018-04-12 2019-10-17 Bayer Aktiengesellschaft N-(cyclopropylmethyl)-5-(methylsulfonyl)-n-{1-[1-(pyrimidin-2-yl)-1h-1,2,4-triazol-5-yl]ethyl}benzamide derivatives and the corresponding pyridine-carboxamide derivatives as pesticides

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2530068A1 (en) * 2003-06-30 2005-01-06 Merck Frosst Canada Ltd. Cyanoalklamino derivatives useful as cathepsin cysteine protease inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0061836A2 (en) * 1981-03-19 1982-10-06 Imperial Chemical Industries Plc Amide derivatives, processes for preparing them, their use as fungicides and pesticidal compositions containing them
US4447446A (en) * 1981-03-04 1984-05-08 Imperial Chemical Industries Plc Certain cyano containing aryl amides, compositions containing same and fungicidal use thereof
JPS60169454A (en) * 1984-02-15 1985-09-02 Mitsui Toatsu Chem Inc Amide-substituted propargyloxyacetonitrile derivative
JPS60255759A (en) * 1984-05-31 1985-12-17 Mitsui Toatsu Chem Inc Amide-substituted fluoroethoxyacetonitrile derivative, its preparation and herbicide and fungicide containing the same
WO1998023581A1 (en) * 1996-11-26 1998-06-04 Basf Aktiengesellschaft Benzamidoaldehydes and their use as cysteine protease inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447446A (en) * 1981-03-04 1984-05-08 Imperial Chemical Industries Plc Certain cyano containing aryl amides, compositions containing same and fungicidal use thereof
EP0061836A2 (en) * 1981-03-19 1982-10-06 Imperial Chemical Industries Plc Amide derivatives, processes for preparing them, their use as fungicides and pesticidal compositions containing them
JPS60169454A (en) * 1984-02-15 1985-09-02 Mitsui Toatsu Chem Inc Amide-substituted propargyloxyacetonitrile derivative
JPS60255759A (en) * 1984-05-31 1985-12-17 Mitsui Toatsu Chem Inc Amide-substituted fluoroethoxyacetonitrile derivative, its preparation and herbicide and fungicide containing the same
WO1998023581A1 (en) * 1996-11-26 1998-06-04 Basf Aktiengesellschaft Benzamidoaldehydes and their use as cysteine protease inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
B.F. CAIN: "2-Acyloxymethylbenzoic Acids. Novel amine protective functions providing amides with the lability of esters", JOURNAL OF ORGANIC CHEMISTRY, vol. 41, no. 11, 1976, EASTON US, pages 2029 - 2031, XP002136841 *
H. BRACHWITZ: "1,2,4-oxadiazole aus N-Acylaminonitrile", JOURNAL F. PRAKT. CHEMIE, vol. 314, no. 3, - 1972, pages 447 - 454, XP000908890 *
M. SEDLAK ET AL.: "Preparation, 1H and 13C NMR spectra of substituted 2-benzoylaminocarboxamides", COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS, vol. 60, 1995, PRAGUE CS, pages 150 - 160, XP002136842 *
T UEDA ET AL: "Syntheses of 2-acylaminoacetamidine and 3-acylaminopropionamidine derivatives", CHEMICAL AND PHARMACEUTICAL BULLETIN,JP,TOKYO, vol. 12, no. 16, 1 January 1968 (1968-01-01), pages 2355 - 2361, XP002075777, ISSN: 0009-2363 *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455502B1 (en) 1999-03-15 2002-09-24 Axys Pharmaceuticals, Inc. Compounds and compositions as protease inhibitors
US6476026B1 (en) 1999-03-15 2002-11-05 Axys Pharmaceuticals, Inc. Compounds and compositions as protease inhibitors
US6593327B2 (en) 1999-03-15 2003-07-15 Axys Pharmaceuticals, Inc. Compounds and compositions as protease inhibitors
EP1248612A4 (en) * 2000-01-06 2005-09-07 Merck Frosst Canada Inc Novel compounds and compositions as protease inhibitors
EP1248612A1 (en) * 2000-01-06 2002-10-16 Merck Frosst Canada Inc. Novel compounds and compositions as protease inhibitors
US6525036B2 (en) 2000-01-06 2003-02-25 Merck & Co., Inc. Compounds and compositions as protease inhibitors
US7064123B1 (en) 2000-12-22 2006-06-20 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
WO2002051983A3 (en) * 2000-12-22 2003-11-06 Axys Pharm Inc Novel compounds and compositions as cathepsin inhibitors
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
WO2002051983A2 (en) * 2000-12-22 2002-07-04 Axys Pharmaceuticals, Inc. Novel compounds and compositions as cathepsin inhibitors
US7196099B2 (en) 2001-09-14 2007-03-27 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
US6977256B2 (en) 2001-11-14 2005-12-20 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin S inhibitors
US7342027B2 (en) 2002-07-26 2008-03-11 Yuhan Corporation 1-phenylpiperidin-3-one derivatives and processes for the preparation thereof
EP2251007A2 (en) 2002-09-24 2010-11-17 Novartis AG Sphingosine-1-phosphate (S1P) receptor agonists for use in the treatment of demyelinating diseases
EP2255798A2 (en) 2002-09-24 2010-12-01 Novartis AG Sphingosine-1-phosphate receptor agonists for use in the treatment of optic neuritis
EP2719700A1 (en) 2008-01-09 2014-04-16 Amura Therapeutics Limited Tetrahydrofuro(3,2-b)pyrrol-3-one derivatives as inhibitors of cysteine proteinases
EP3011958A1 (en) 2008-06-20 2016-04-27 Novartis AG Paediatric compositions for treating multiple sclerosis
EP3545953A1 (en) 2008-06-20 2019-10-02 Novartis AG Paediatric compositions for treating1 multiple sclerosis
WO2019197468A1 (en) * 2018-04-12 2019-10-17 Bayer Aktiengesellschaft N-(cyclopropylmethyl)-5-(methylsulfonyl)-n-{1-[1-(pyrimidin-2-yl)-1h-1,2,4-triazol-5-yl]ethyl}benzamide derivatives and the corresponding pyridine-carboxamide derivatives as pesticides
IL277777B1 (en) * 2018-04-12 2023-06-01 Bayer Ag N-(cyclopropylmethyl)-5-(methylsulfonyl)-n-{1-[1-(pyrimidin-2-yl)-1h-1,2,4-triazol-5-yl]ethyl}benzamide derivatives and the corresponding pyridine-carboxamide derivatives as pesticides

Also Published As

Publication number Publication date
EP1157003A1 (en) 2001-11-28
GB9903861D0 (en) 1999-04-14
JP2002537285A (en) 2002-11-05
AU2560700A (en) 2000-09-04

Similar Documents

Publication Publication Date Title
EP1155010A1 (en) Acetamido acetonitrile derivatives as inhibitors of cathepsin l and/or cathepsin s
KR100629186B1 (en) Benzamide derivatives for the treatment of diseases mediated by cytokines
WO2000049008A1 (en) Di- and tripeptide nitrile derivatives as inhibitors of cathepsin l and cathepsin s
ES2246830T3 (en) DERIVATIVES OF AMIDA.
ES2211172T3 (en) DERIVATIVES OF BENZAMIDA AND ITS USE AS INHIBITORS OF CYTOKINES.
ES2712803T3 (en) Histone deacetylase inhibitors
CZ300293B6 (en) Novel amide derivatives, process of their preparation and pharmaceutical composition in which they are comprised
MXPA01000895A (en) Amide derivatives useful as inhibitors of the production of cytokines.
SK284665B6 (en) Heterocyclic derivatives which inhibit factor Xa, pharmaceutical compositions containing them, processes for the preparation thereof and their use
CZ301971B6 (en) Amide derivative, process for its preparation, pharmaceutical composition containing thereof and the use of the derivative for preparing a medicament
KR20010089284A (en) Chemical compounds
TW200843752A (en) Novel diamide derivative
EP1157003A1 (en) Acylated aminoacetonitriles as cysteine protease inhibitors
JP2008524191A (en) 4- (4- (imidazol-4-yl) pyrimidin-2-ylamino) benzamide as a CDK inhibitor
EA014324B1 (en) Triazolophthalazines
JPWO2005080392A1 (en) Pyrazoloquinolone derivatives and uses thereof
JP2013509412A (en) Imidazopyridines as novel scaffolds in multitarget kinase inhibition
KR101151530B1 (en) Amide derivatives bearing a cyclopropylaminocarbonyl substituent useful as cytokine inhibitors
WO1999059526A2 (en) Protease inhibitors
WO2001030772A1 (en) Compounds and their use as cysteine protease inhibitors
JPH07509257A (en) Mercaptamide derivatives useful as neutral endopeptidases and ACE inhibitors
US6277871B1 (en) Inhibitors of protein isoprenyl transferases
CZ2001439A3 (en) Amide derivatives that are useful as inhibitors of cytosine production, process of their preparation and pharmaceutical preparation in which they are comprised
CZ20011093A3 (en) Amide derivatives that are useful as inhibitors of cytokine production, process of their preparation and pharmaceutical preparation in which they are comprised
MXPA00010432A (en) Benzamide derivatives for the treatment of diseases mediated by cytokines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000903853

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 599733

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09913754

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000903853

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000903853

Country of ref document: EP